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Two studies were performed to determine the effects of resistant starch (RS) on body 
weight and fat. A 2x2 factorial design was used in both studies, and results were considered 
significant when p<0.05 for both studies. The first study examined the effects of RS in a high fat 
diet (44.8% of energy) on weight, fat, peptide-YY (PYY) levels, and cecal pH in male Sprague-
Dawley rats. Rats were fed a low fat energy control diet for one week prior to diet treatment. On 
week two, rats were blocked by weight and fed one of the following diets for 12 weeks (n=10): 
low fat, energy control (LFEC); LF resistant starch (LFRS); high fat, energy control (HFEC); or 
high fat resistant starch (HFRS). RS did not lower ight or fat with either the HF or LF diets. 
RS consumption resulted in greater full and empty cecal weights, and a lower pH for the LFRS 
diet. This data indicate fermentation, even though weight and fat loss did not occur. This is 
contrary to previous reports with RS, which has been shown to decrease body fat compared to 
controls. The second study examined the effects of RS on the weight, fat, PYY levels, and 
glucagon-like peptide-1 (GLP-1) levels in female Sprague-Dawley rats. Ovariectomized (OVX) 
rats were used to represent rats prone to gaining wei ht, and sham rats represented normal rats. 
Rats were assigned to one of four groups (n=10): OVEC, OVRS, SHEC, or SHRS. Rats were fed 
the EC diet for 6 weeks prior to diet treatment to gain weight after surgery, and then blocked by 
weight and fat into diet treatment groups, and spent 13 weeks on treatment diets. Energy intake, 
total gastrointestinal weight, large intestine/cecum weight, and small intestine weight were all 
higher in RS fed rats relative to EC fed rats. Mesenteric, ovarian, perirenal, retroperitoneal, and 
total fat pads were lower in RS rats relative to ECrats. Although RS was not effective in 
lowering body weight or body fat in the first study, the data indicates that resistant starch may 





Overweight and obesity continue to be a growing problem in the United States among 
children, adolescents, and adults and across all ethnicities. According to Ogden et al, in 2003-
2004, the prevalence of obesity among men and women were 31.1% and 33.2%, respectively. 
Data for female children and adolescents show an increase in the prevalence of overweight from 
13.8% in 1999-2000 to 16% in 2003-2004, while male children and adolescents increased from 
14% to 18.2% in the prevalence for overweight in these same years. According to the data by 
Ogden et al, approximately 30% of non-Hispanic white adults were classified as obese in 2003-
2004, as well as 45% of non-Hispanic black adults and 36.8% of Mexican Americans (Ogden et 
al., 2006). With this growing prevalence among a variety of ages, races, and genders, 
overweight, defined as a body mass index (BMI) of 25-29.9, and obesity, defined as a BMI of ≥ 
30, are major public health concerns in the United States and many other countries across the 
globe (Grudy, 2004; Ogden et al., 2006). This concern is due to its association with other life-
threatening medical conditions such as cardiovasculr disease (Grudy, 2004), diabetes (Mokdad, 
2001) hypertension (Montani, Antic, Yang, & Dulloo, 2002), and a variety of cancers (Wellman 
& Freidberg, 2002). Because of these comorbidities, it i  evident that prevention and treatment of 
overweight and obesity are of extreme importance.  
Obesity can be attributed to a plethora of factors, and may also be the result of a multi-
factorial environment. In the westernized society, however, overweight and obesity are often 
credited to the consumption of a high fat diet because of its relatively high energy value (Roy et 
al., 2003). Diets high in fat are generally considere  more palatable and flavorable (Seidell, 
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1998), which can lead to even more consumption. Another population affected by an increase in 
body fat is postmenopausal women. Upon cessation of menstruation, the hormone estrogen is no 
longer produced and released (Danilovich et al., 2000). Estrogen has been well established as a 
factor in energy metabolism, and its absence is associated with fat accumulation (Shimizu et al., 
1997). The postmenopausal woman has 20% more body fat (Ley, Lees, & Stevenson, 1992), and 
puts her at risk for cardiovascular and diabetic complications (Lean, Han, & Seidell, 1998).  Diet 
therapy is among the possible treatment options for both of these causes of weight gain and has 
the potential to reduce body fat.  
  Of the selection of foods targeted for therapeutic se in the treatment and management of 
obesity, starches and dietary fiber have received much attention or their effects on food intake 
and weight status. Studies have reported that these foods do so by a variety of mechanisms, such 
as by promoting satiety sooner, by slowing gastric emptying (Stephen, 1991; Anderson, Smith, 
& Gustafson, 1994), by diluting energy of the diet (Topping & Clifton, 2001), and by decreasing 
the absorption of fatty acids (Van Horn, 1997). Resistant starch, in particular, may be a useful 
tool in combating obesity. Dietary resistant starches are defined as non-digestible fibers that 
resist, to varying degrees, amylase digestion in the small intestine and are fermented to short-
chain fatty acids (SCFA) by microflora in the large intestine (Higgins, 2004). Resistant starch 
has many similar effects as dietary fiber and may also help in reducing body weight and body fat, 
as well as protecting against colorectal cancer (Topping & Clifton, 2001) and reducing 
postprandial glycemia and insulinemia (Raben et al., 1994). The production of SCFAs, mainly 
acetate, propionate, and butyrate (Topping & Clifton, 2001), when resistant starch is fermented, 
reduces the pH of the gut and may have an important ole in reducing body weight and fat (Silvi, 
Rumney, Cresci, & Rowland 1999).  
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The mechanism by which resistant starch may aid in weight loss is through increasing the 
gene expression and production of peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) in 
the gut via the production of the SCFAs (Keenan et al., 2006a). Both of these gastrointestinal 
peptides have been shown to reduce food intake (Batterh m et al., 2003; Hillebrand, de Wied, & 
Adan, 2002). If this is the means by which resistant starch reduces food intake and lowers body 
weight and fat, animals fed diets containing resistant starch will have higher circulating blood 
levels of PYY and GLP-1. Resistant starch is also kn wn to dilute the energy density of the diet 
in the same way as fermentable fibers, although not as much as non-fermentable fibers. 
However, resistant starch as a fermentable fiber fed to animals showed increased gene 
transcription for PYY and proglucagon in cecal epithelial cells, increased large intestine gene 
transcription for PYY and proglucagon, and greater plasma levels of PYY and GLP-1 compared 
to non-fermentable fibers. Acting in the same way as a fermentable fiber, resistant starch has also 
been shown to help reduce abdominal fat in rats (Keenan et al., 2006a). For these reasons, 
resistant starch is implicated as a promising tool in the management and treatment of obesity.  
 Study 1 will determine the effects of resistant starch on rats fed high fat (HF) and low fat 
(LF) diets. Study 2 will determine the effects of resistant starch on the weight and body fat of 
bilaterally ovariectomized (OVX) rats versus sham-operated rats (SH). OVX female rats will be 
used because they are known to gain body fat due to the lack of estrogen, and are a good model 
to test the hypothesis that resistant starch reduces body fat using an endocrine model of obesity 
(Ainslie, 2001).  
OBJECTIVES 
 The objectives of Study 1 are to determine the effcts of resistant starch on weight, body 
fat, and, cecal weights, and gut signaling of rats on a high fat diet. The objectives of Study 2 are 
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to determine the effects of resistant starch on the weight, body fat, and gut signaling of OVX rats 
and SH rats, and also to determine the effects of resistant starch on cecal weights as an indicator 
of fermentation. 
HYPOTHESIS 
 It is hypothesized that obesity-induced animals fed a diet containing resistant starch will 
have lower body weight, lower percentage of body fat, lower abdominal fat, greater 
fermentation, and greater plasma levels of PYY and GLP-1 than those fed a diet without resistant 
starch.  
ASSUMPTIONS 
• It is assumed that the rat model will have a digestv  physiology and a habitual diet with 
a composition as close as possible to humans. 
• It is assumed that abdominal fat will correlate to total body fat.  
• It is assumed that all measurements from the studies will be taken and recorded correctly. 
• It is assumed that animal blood and tissue collections are representative of human 
subjects. 
LIMITATIONS 
• Not all of the same measurements were taken for both studies.  
• NMR was deemed not effective as a measure of total b dy fat.  
• Although the rat model has a similar digestive physiology to that of humans, the results 





REVIEW OF LITERATURE 
DIETARY FIBER 
Dietary fiber is considered a group of non-starch polysaccharides and lignins of plant 
origin (Liu et al., 2002; Ajani, Ford, & Mokdad, 2004) that are resistant to digestion by 
gastrointestinal enzymes in humans and most animals (Burton-Freeman, 2000; Brown, Rosner, 
Willett, & Sacks, 1999) with complete or partial fermentation in the large intestine, although a 
universal definition is yet to be established (Nugent, 2005). Sources of fiber often include fruits, 
vegetables, grain products, legumes, and other sources such as oat and wheat bran (Burton-
Freeman, 2000). Fiber can be divided into two groups: soluble fibers that form gels in the 
presence of water, or insoluble fibers. The soluble fi rs include pectins, gums, mucilages, and 
some hemicelluloses, whereas lignins, celluloses, and the remaining hemicelluloses make up the 
insoluble fibers (Brown, Rosnar, Willett, & Sacks, 1999). However, the Institute of Medicine 
(IOM) suggests categorizing dietary fiber in another manner: by its physiochemical properties 
instead. The terms viscous and fermentable are often now used to describe fibers (Queenan et al., 
2007). Other physical properties of dietary fiber include bulk/volume, water-holding capacity, 
and adsorption/binding (Burton-Freeman, 2000), with d fferent sources of fiber causing different 
bodily responses (Liu et al., 2002). Because of these characteristics and the resulting physiologic 
effects, this food group has gained much attention lately from both the public and scientific 
communities for its numerous health implications. It has the ability to modify physiologic 




Dietary fiber has been shown to be positively associated with cardiovascular health. In a 
prospective cohort, data showed an inverse relationship between dietary fiber intake and 
cardiovascular disease (CVD) and myocardial infarction (Liu et al., 2002). Another prospective 
study showed higher consumption of fiber in the diet was correlated with lower concentrations of 
C-reactive protein, a marker of inflammation and possible predictor of cardiovascular events. 
(Ajani, Ford, & Mokdad, 2004). Soluble fiber has been shown to significantly reduce total 
cholesterol levels, as well as low density lipoprotein (LDL): high density lipoprotein ratio (HDL) 
(Jenkins et al., 2002). This data plus other scientif c evidence further support the reported 
negative correlation between fiber and CVD, and the benefit of dietary fiber intake on heart 
health.  
Research looking at the relationship between consuming fiber and colon health also 
seems promising. First of all, fiber normalizes colonic function by increasing fecal weight and 
bowel frequency (Correa-Matos et al., 2003). In an international correlative study, starch intake 
was inversely related to both colon and rectal cancer (Cassidy, Bingham, & Cummings, 1994). In 
a prospective study investigating the relationship between fiber intake and diverticular disease, 
both soluble and insoluble fibers were inversely associated with risk of developing diverticular 
disease. Insoluble fiber, however, had a stronger inverse relationship (Aldoori et al., 1998). 
Doubling fiber intake in populations that consumed v ry little fiber correlated with up to a 40% 
decrease in colorectal cancer risk (Bingham et al., 2003). McBurney (1994) reported that 
consumption of fiber in diets for long-term is associated with several changes in the intestinal 
milieu, including a change in mass, length, villus appearance, cell proliferation rates, and 
enterocyte migration along the crypt-villus axis.  
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Diets high in dietary fiber and complex carbohydrates have also been linked to improved 
insulinemia. Because of its ability to retard gastric emptying, nutrients in meals consumed with 
fiber are absorbed relatively distally in the small intestine, which reduces the amount of gastric 
inhibitory polypeptide (GIP) released. GIP is normally secreted in the proximal small intestine, 
and is also known to induce insulin release, which can promote hyperinsulinemia (Marshall, 
Bessesen, & Hamman, 1997). The fact that it also delays gastric emptying may be beneficial 
regarding blood glucose attenuation because of a delayed release of postprandial glucose when 
consumed (Nugent, 2005; Queenan et al., 2007)), as well as lowered insulin requirements 
(Anderson et al., 1995). 
Along with the above mentioned health benefits, the rol  of fiber in the diet has been 
associated with a lower risk of obesity, and it may do so by multiple mechanisms. First of all, it 
has been suggested that fiber consumption induces satiety and satiation, mostly due to its bulking 
effect (Schneeman & Tietyen, 1994). Research suggests that viscous fibers may delay gastric 
emptying, causing a prolonged sensation of fullness, which would result in less consumption of 
food (Queenan et al., 2007). Secondly, fiber affects energy density by displacing energy if a 
person is consuming a specific volume of food versus a certain amount of energy, which has 
been shown in men in a study by Rolls et al (1998). It has also been suggested that dietary fiber
disrupts fat and carbohydrate absorption by delayed gastric emptying, and the interference with 
digestive enzymes and the intestinal surface. By this method, fiber would also affect the amount 
of calories absorbed (Schneeman & Tietjen, 1994). 
The benefits of consuming dietary fiber are quite pronounced in research. In fact, the 
consequences of rodents fed diets completely lacking in fiber included atrophy of the small 
intestine and colon, with supplementation of the dit with fiber reversing these effects (Slavin, 
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Nelson, McNamara, & Cashmere, 1985; Ecknauer, Sircar, & Johnson; 1981). It seems that 
dietary fiber may be beneficial for those at risk for CVD, diabetes, or even obesity. For these 
reasons, the National Academy of Sciences recommend 38 and 25 grams of dietary fiber per day 
for men and women, respectively (Lupton, 2003).  
FERMENTABLE FIBERS AND SHORT CHAIN FATTY ACIDS 
 Carbohydrates in the colon can affect its physiology by being both physically present or 
being the substrate of fermentation (Topping & Clifton, 2001). The microflora of the gut 
primarily use carbohydrates as an energy source (Jacobasch et al., 1999). If fiber or starch 
somehow bypasses the small intestine, anaerobic fermentation of these fibers by bacteria can 
occur in the large intestine, yielding short chain fatty acids (SCFAs), hydrogen, carbon dioxide, 
and methane (MacFarlane & MacFarlane, 2003) and metabolizable energy for microbial growth 
(Topping & Clifton, 2001). Butyrate, acetate, and propionate are the main SCFAs produced, but 
others can be produced in lesser amounts (MacFarlane & MacFarlane, 2003). Colonocytes use 
SCFAs as a fuel source, supplying ~60-70% of the colonic energy needs, with butyrate being the 
preferred fuel even when glucose is available (Topping & Clifton, 2001). Often propionate is 
favored as well, with both formed into ATP for energy for colonocytes (Jacobasch et al., 1999). 
The production of SCFAs increases blood flow in thecolon, lowers luminal pH, aids in the 
prevention of abnormal colonic cell population development (Topping & Clifton, 2001), 
regulates colonocytes’ gene expression, cell cycle, and apoptosis, and also exerts trophic effects 
on the epithelium of the colon (Mentschel & Claus, 2003). Fermentable fibers can also increase 
the abundance of lactic acid bacteria, which further aid in the fermentation of fibers (Russel & 
Diez-Gonzales, 1998), and the prevention of potential pathogens that are pH-sensitive, 
categorizing them as a prebiotic (Topping & Clifton, 2001). For this reason, they have been 
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added to some oral electrolyte solutions (Oli, Petschow, & Buddington, 1998). Overall, SCFAs 
improve the digestive and absorptive capabilities of the colon (Rombeau & Kripe, 1990; 
Tappenden et al., 1997). Levels of SCFAs are highest in the proximal colon, where fermentation 
is greatest, and levels decrease further down the gut as colonocytes use them, with very little 
amounts found in the distal colon. Interestingly, most colon cancers and other colonic diseases 
occur in the distal colon, suggesting the importance of SCFAs in colonic health (Topping & 
Clifton, 2001). The lowered pH of the lumen upon production of SCFAs is also thought to be 
protective against colon cancer (Young & Le Leu, 2004).  
 Research on fermentable fibers and the resulting SCFAs that are produced verify the 
benefits of maintaining the health of the colon. Ferm ntable fibers can be used to help recover 
from diarrhea (Buddington & Weiher, 1999). Correa-Mtos et al. (2003) found that consumption 
of fermentable fibers reduced the recovery time and improved symptoms of induced S. 
typhimurium infection in neonatal piglets indicated by stool cnsistency and maintenance of 
physical activity. It is also believed that SCFAs may help prevent foreign bacteria from 
penetrating the small intestine and colon (Reardon & Tappenden, 1999). In dogs fed a diet with 
fermentable fibers, it was shown that their intestines were longer, had increased surface area, and 
greater mucosal mass compared with those fed a poorly fe mentable fiber (Buddington, 
Buddington, & Sunvold, 1999).  
Data has also shown that fiber-induced fermentation causes the release of particular 
gastrointestinal hormones. In canines, glucagon-like peptides (GLP-) 1 and 2, and GIP, which 
aid in mucosal growth and upregulation of transport rocesses in the proximal colon, were all 
increased (McBurney et al., 1998). In rats fed fermentable fibers, there was an increase in 
intestinal proglucagon (the precursor to glucagon) mRNA and thus greater postprandial GLP-1 
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was released (Reimer & McBurney, 1996), although this increase in proglucagon was not seen in 
a later study by Reimer et al. (2000). However, increased concentration of proglucagon-derived 
peptides has been observed by others once fermentabl  fibers were fed (Gee et al., 1996; 
Massimino et al., 1998), as well as smaller oscillations in blood glucose concentrations 
(Massimino et al., 1998). GLP-1 additionally stimulates insulin secretion, inhibits glucagon 
secretion, and delays gastric emptying, all of which are beneficial in diabetic patients (Holst, 
1997). The ability of fermentable fibers to promote GLP-1 secretion makes it a target for 
treatment in diabetic patients. SCFA production is al o associated with an increase in the 
gastrointestinal hormone peptide YY (PYY), which has been shown to inhibit gastric emptying 
(Cherbut, 1998) and reduce food intake (Batterham, 2003).  
 The SCFA butyrate particularly has been studied for its role in colonic health. It acts as a 
signal metabolite, stimulating cell migration and proliferation (Valezquez, Lederer, & Rombeau, 
1996). Research has also shown that butyrate has slightly different functions in neoplastic 
colonic cells than in normal epithelial cells. It affects gene expression and may induce apoptosis, 
killing off any possible damaged and potentially harmful colonocytes while inhibiting 
proliferation (Jacobasch et al., 1999; Mentschel & Claus, 2003), and has been shown to reverse 
neoplastic changes in vitro (Ferguson et al., 2000). In normal cells, apoptosis has been observed 
in the absence of butyrate (Hass et al., 1997). Segain et al (2000) has also reported that butyrate 
inhibits Nuclear Factor-kappa B (NF-κB), a key regulator in inflammatory response. Those 
suffering from inflammatory bowel disease have increased activity of NF-κB, suggesting that 
butyrate can potentially reduce the immune response. I  fact, patients with ulcerative colitis and 
colon cancer have been reported to have low levels of butyrate (Chapman et al., 1994). 
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Concerning weight management, butyrate has been reported to increase gene expression of PYY 
and proglucagon and may participate in satiety (Zhou et al., 2006) 
Research also suggests that other SCFAs can be beneficial for health. Propionate has 
been shown to suppress fatty acid and cholesterol synthesis in vitro (Berggren, Nyman, & 
Lundquist, 1996) and in vivo (Chen et al., 1984), although this is not agreed by all (Queenan et 
al., 2007). Propionate is also confirmed to kill E. coli in an acidic environment (Cherrington et 
al., 1991). Acetate has been shown to decrease free fatty acid availability in humans and inhibit 
cholesterolgenesis in rats (Beynen, Buechler, & Van Der Molen, 1982), and Abrahamse et al 
(1999) reported that acetate inhibits DNA oxidative damage due to H2O2 in the rat colon. Both 
propionate and acetate have been observed to induce apoptosis like butyrate in tumorigenic cells. 
However, they do so to a lesser extent and require higher concentrations (Hague et al., 1995). 
Butyrate, propionate, and acetate have all been associ ted with greater colonic blood flow 
(Mortensen et al., 1991; Kvietys & Granger, 1981), enhancing tissue oxygenation and transport 
of absorbed nutrients (Topping & Clifton, 2001). 
Any fermentable fibers or starches that produce SCFAs, especially butyrate, thus may be 
targeted for improving gut health and preventing possible pathology from developing. The 
delivery of butyrate to the distal colon may be particularly important because of its susceptibility 
to diseases relative to the proximal colon (Topping & Clifton, 2001). The effect of SCFAs on 
hormone secretion, particularly GLP-1 and PYY, is of great interest regarding weight 
management.  
RESISTANT STARCH 
 Starch is the polysaccharide storage form of glucose f und in plants, and is a major 
source of carbohydrates in the diet (Nugent, 2005; Sajilata, Singhal, & Kulkarni, 2006). It is 
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packaged as granules in two forms: the polymer amylose consisting of linear glucose residues 
connected by α-D-(1-4) linkages, or the branched polymer amylopectin onsisting of the same 
linear α-D-(1-4) linkages plus branched α-D-(1-6) linkages. Starch is usually hydrolyzed by the
enzymes α-amylases, glucoamylase, and sucrose-isomaltase in the small intestine (Nugent, 
2005); however, this is not the case for all starches. In 1982, Englyst and colleagues found that 
not all starch was hydrolyzed by enzymes, and this remainder was termed “resistant starch” 
(Englyst, Wiggins, & Cummings, 1982). Resistant starch, as the name implies, refers to the 
portion of starch that resists digestion into free glucose and absorption in the small intestine, 
bypassing it and reaching the large intestine where it is fermented by colonic microflora. This 
fermentation process, like dietary fiber, results in the production of SCFAs (butyrate, acetate, 
and propionate), as well as carbon dioxide, methane, hydrogen, and organic acids. However, 
unlike dietary fiber, fermentation of RS produces more butyrate and less acetate (Nugent, 2005; 
Sajilata, Singhal, & Kulkarni, 2006).  
Resistant starch (RS) is resistant to mammalian enzymes due its structure, and four types 
exist: RS1, RS2, RS3, and RS4. RS1 refers to a physically inaccessible form of starch that is 
physically protected because the intact plant structu e of amyloblasts hinders enzymatic 
degradation. RS2 refers to starch in a certain granular form that is ightly packed in a radial 
pattern, limiting its accessibility to enzymes. RS3 refers to retrograded amylose formed during 
cooling of gelatinized starch, and is the most resistant form of RS by mammalian digestive 
enzymes, but still degradable by microbial fermentation. Finally, RS4 refers to the formation of 
new chemical bonds other than the α-D-(1-4) and α-D-(1-6) linkages found in starch (Jacobasch 
et al., 1999; Sajilata, Singhal, & Kulkarni, 2006), and includes starches that have been etherized, 
esterified, or cross-bonded with chemicals that reduc  their digestibility (Nugent, 2005). Natural 
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food sources of RS include bananas and legumes (Sajilata, Singhal, & Kulkarni, 2006), and can 
be found in some amounts in any food containing starch (Nugent, 2005). Most humans tend to 
consume RS from cooked sources, such as cooked potatoes, breads, and pastas, and these natural 
sources are usually affected by processing and storage conditions. Commercially available 
sources of RS, on the other hand, such as Hi-maize® or CrystaLean® (Nugent, 2005), are 
unlikely to be affected by such conditions (Sajilata, Singhal, & Kulkarni, 2006). The commercial 
sources have other advantageous properties that make them useful for incorporating into food 
products, including bland in flavor, fine particle size, increasing the bowl life of breakfast 
cereals, and being a functional food component. Andjust as there are different forms of RS, each 
form may have a slightly different physiological response. Also the amount consumed, what else 
was consumed at the time, and the cooking conditions all may affect the physiological response 
as well (Nugent, 2005). 
In addition to these forms affecting the resistance of starch, a higher ratio of 
amylose:amylopectin also lowers the digestibility of starch, with the linear amylose chains 
forming a packed structure of cross linkages secured by hydrogen bonds upon retrogradation. 
Amylopectin can interfere with this structure formation during retrogradation (Berry, 1986). 
Repeated cycles of heating then cooling can increase the retrogradation process (Annison & 
Topping, 1994).  Cooking can also affect the RS content in food, with high moisture and 
temperature processes disturbing the crystalline structure of RS, thus lowering the content 
(Sajilata, Singhal, & Kulkarni, 2006). Another factor influencing RS is the addition of 
endogenous lipids, which can complex with amylose and possibly disrupt the formation of RS 
(Eerlingen et al., 1994). Finally, fermentation can reduce the content of RS, as is the case in the 
large intestine when it is broken down by the gut microflora.  
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Although it is a starch, RS shares similar physiologic properties and health benefits with 
soluble fiber, as well as benefits unique to its own as an insoluble component of the diet. Both 
RS and soluble fiber are slow to digest, with RS digestion usually occurring 5-7 hours after 
consumption, and result in slower, more controlled glycemic response and lowered postprandial 
insulinemia and potentially increasing satiety (Jenkins et al., 1987; Raben et al., 1994). This 
response is most likely due to the replacement of digestible starch found in other foods with the 
indigestible starch (Jenkins, 2002). RS and soluble fi r are both poorly digested in the small 
intestine, but highly fermented in the large intestine with SCFA production (Bjorck et al., 1987; 
Goni et al., 1996; Sajilata, Singhal, & Kulkarni, 2006). RS, however, is not viscous like soluble 
fiber upon arrival in the large intestine (Nugent, 2005), and has been reported to produce a larger 
proportion of butyric acid than fiber does (Akerberg et al., 1997). It is estimated that about 30-
70% of RS is metabolized in the colon with the remainder excreted (Behall & Howe, 1995).  
Data supports that RS confers several health benefits. It has been shown to be beneficial 
to the colonic milieu, including increasing crypt cell production rate, decreasing large intestinal 
cell atrophy (Sajilata, Singhal, & Kulkarni, 2006), increasing fecal weight and output, reducing 
fecal and cecal pH (Cassand et al., 1997), decreasing mmonia levels, and altering the activity of 
bacterial enzymes in a beneficial manner (Silvi et al., 1999) relative to a lack of fiber. Butyrate 
produced from fermentation of RS is an energy substrate for colonic cells and has been shown to 
inhibit malignant transformation of colonic cells in vitro (Asp & Bjorck, 1992). RS has also been 
studied as a treatment option for ulcerative colitis. In a study by Jacobasch et al (1999), rats with 
chemically induced colitis and fed RS showed earlier sign of improvement for markers of 
inflammation compared to controls. Studies show that RS affects expression of a number of 
receptors on T- and B- lymphocytes and macrophages, which are all involved in immune 
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function (Sotnikova et al., 2002), and inhibits NF-κB through butyrate production (Segain et al., 
2000). The noted impact on immune response may be of interest regarding inflammatory bowel 
disease. Because of its tendency to affect the microbial population, RS may also function as a 
prebiotic stimulating the growth of beneficial bacteria of the gut while suppressing the 
pathological ones (Young & Le Leu, 2004; Sajilata, Singhal, & Kulkarni, 2006).  
Beyond the colon, RS, like fiber, has also been linked to reduced serum cholesterol and 
triglyceride levels in animal models (Younes t al., 1995; Mathe et al., 1993) and human subjects 
(Behall, Scholfield, Yuhaniak, & Canary, 1989; Behall & Howe, 1995). Consumption of RS has 
been associated with decreased incidence of gallstone  as well (Malhotra, 1968). Like dietary 
fiber, it is associated with decreased postprandial glucose and insulin responses, which would be 
of particular interest in diabetic treatment (Haralmpu, 2000). 
In addition to its numerous health implications, several studies have supported the use of 
RS as a treatment option for weight management. Results from several animal studies indicate 
that consumption of RS may lead to weight loss or reduced weight gain. For example, De 
Deckere et al (1993) reported lowered fat pad weight and decrease adipocyte cell size, and this 
has been confirmed by other studies (Lerer-Metzger et al., 1996; Kabir et al., 1998a) 
Consumption of RS was associated with a decrease in GLUT-4 expression, an insulin-regulated 
protein responsible for glucose uptake (Kabir et al., 1998b). Younes et al (1995) reported a 
decrease in the activity of lipogenic enzymes 3-hydroxy-3-methylglutaryl-Co A and fatty acid 
synthase, which are involved in cholesterol synthesis and fat synthesis, respectively. Another 
study has shown that RS increases the expression of the LDL receptor in the liver of rats 
(Fukushima, 2001). Mathe et al (1993) demonstrated that RS increased bile acid seretion, which 
can also affect lipid metabolism. Recently, Keenan et al (2006a) reported that RS-fed rats had 
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lower abdominal fat relative to a control group, even though their food intake was not different 
from the control.  
There are a few possible leads as to how RS affects body weight. Most of the research 
involved in this area focuses on the anaerobic bacteri l fermentation of RS into SCFA, and it is 
through these acids that RS is thought to help in limiting weight gain (Topping, Fukushima, & 
Bird, 2003). When compared to a non-fermentable fibr, RS had greater amounts of SCFAs 
produced, along with increased transcription of PYY and proglucagon, and increased plasma 
levels of PYY and GLP-1 (Keenan et al., 2006). PYY is normally released in the gut in 
proportion to the amount of calories ingested (Adrian et al., 1985) and is a gut-signaling 
hormone indicating food intake in the brain (Batterham, 2002). As stated earlier, PYY has been 
shown to reduce food intake and weight gain when infused in human subjects, and lower 
endogenous PYY levels have been observed in obese subj cts (Batterham et al., 2002). Long-
term administration of PYY in murine models has demonstrated decreased weight gain 
(Batterham, 2003). GLP-1 is also released in respone to food ingestion (Deacon, 2005), and acts 
as a meal termination signal and food regulation (Kreymann et al., 1987; Flint, Raben, Astrup, & 
Holst, 1998). With the increase of these two peptides, it is suggested that the RS-produced 
SCFAs are a natural and endogenous method to reduce nergy intake and hopefully body weight 
(Keenan et al., 2006a).  
Although SCFA production in relation to RS fermentation is highly studied, other 
putative mechanisms may also be responsible for its role in weight management. First of all, the 
metabolizable energy value of RS has been calculated to be ~2 kcal/g, whereas digestible 
carbohydrates have an energy value of ~4 kcal/g (Livesey, 1994). This displacement of kcals by 
the addition of RS in the diet can displace the total amount of kcals consumed in a day, thus 
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resulting in a decreased overall caloric intake, just as with dietary fiber. Higgins et al (2004) 
reported that replacing 5.4% of total carbohydrates with RS in the diet could increase 
postprandial lipid oxidation. They suggest that this mechanism could help reduce fat 
accumulation in the long term. Also, foods rich in RS may cause a reduced insulin response due 
to its lowered glycemic response. Ultimately, this may make fat more accessible for energy use 
(Tapsell, 2004). It has been suggested that RS may also promote satiety, although this is still 
controversial (Nugent, 2005). These examples are supplementary ways as to how RS may work 
in the treatment of obesity and in weight management.  
Overall, research agrees that the effects of RS are advantageous to the body with much 
potential nutritional and commercial value (Asp, Amelsvoort, & Hautvast, 1996). It has a wide 
range of influence, affecting fermentation in the gut, fecal bulking and transit time, colonic 
bacterial growth, postprandial glycemia and insulinemia, and energy value of foods (Abia et al., 
1993; Annison & Topping, 1994). However, there are some concerns with consumption of RS 
regarding bloating, flatulence, belching, mild laxative effects and stomach aches when RS is 
consumed in larger amounts (~30g/day or more) (Heijnen, 1996). Other than these discomforts, 
the potential physiological benefits of RS are obviusly similar to dietary fiber, although it is 
considered a starch. And it is because of these similar ties that deem it worthy of being 
categorized as a component of dietary fiber to some (De Vries, 2003). Data also confers that RS 
as part of the diet can be used in weight loss and/or management. And although RS does produce 
energy through fermentation, this energy value is still less than digestion of starch in the small 
intestine (Englyst, Kingman, Hudson, & Cummings, 1996). Whether this starch’s influence on 
body weight and body fat is solely due to the production of SCFAs upon fermentation and the 
subsequent increase in PYY and GLP-1, or other mechanisms is not yet clear. More research is 
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needed to distinguish its exact manner, but for now its use in the treatment of obesity seems 
extremely promising.  
ENDOCRINE OBESITY 
 Overweight and obesity are growing problems worldwide, with numerous factors 
contributing to their cause. Increased energy intake nd decreased energy output are often the 
blame for the sudden epidemic. Increased fat accumulation due to endocrine changes is a lesser 
known cause of obesity, but may also be responsible for the increased rates due to its resulting 
metabolic alterations. Particularly, the hormone estrogen has been investigated for its role in 
energy homeostasis.  
 It is well understood that the postmenopausal period is related to a striking change in 
endocrinology (Burger et al., 1995). In postmenopausal women, the ovaries lose their ability to 
function, including the production and release of estrogen (Danilovich et al., 2000). It has been 
known for some time that the decrease in estrogen production that results during menopause is 
followed by a characteristic increase in body fat (Shimizu et al., 1997; Toth, Tchernof, Sites, & 
Poehlman), with fat accumulation occurring more likly in the upper body, mainly the abdominal 
area, rather than lower (Tremollieres, Pouilles, & Ribot, 1996; Gambacciani et al., 1996) putting 
the postmenopausal woman at increased risk for developing CVD and diabetic complications 
(Lean, Han, & Seidell, 1998). In fact, postmenopausal women have 20% more body fat 
compared to premenopausal women (Ley, Lees, & Stevenson, 1992). 
 In the murine model, lack of estrogen production ca  modify metabolism resulting in 
obesity, skeletal abnormalities, and infertility (Danilovich et al., 2000). The ovariectomy 
procedure in rats ceases estrogen production and imitates the symptoms of menopause. This 
procedure has been shown to increase body weight by many (Kakolewski, Cox, & Valnstein,  
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1968; Ainslie et al., 2001), and was reported to do so by 22% in just 10 weeks (Kakolewski, 
Cox, & Valnstein, 1968). In one study that disrupted he follicle-stimulating hormone receptor 
(FSH-R) in mice by using a knockout model, which also terminates estrogen production, an 
increase in abdominal fat deposition, curvature in the spinal column, and a decrease in bone 
weight all occurred. Replacement of estrogen in these knockout mice reversed the adipose 
accumulation (Danilovich et al., 2000).  Mice of both sexes that have the estrogen receptor-alpha 
knocked-out display increased white adipocyte tissue (WAT) and hyperplasia (Heine et al., 
2000). Another study showed that mice deficient in aromatase, the enzyme responsible for the 
production of estrogen, developed fatty livers and ha more abdominal adipose tissue. The study 
concluded that the fat accumulation was a result of a combination of reduced physical activity 
and glucose oxidation (Jones et al., 1997). Ainslie et al (2001) reported that ovariectomized rats 
were hyperphagic, had lower levels of spontaneous phy ical activity, and a similar resting energy 
expenditure compared to sham-operated rats, all of which resulted in weight gain. 
Ovariectomized rats treated with estradiol had similar body weights, energy intakes, and physical 
activity levels to that of sham rats.   
 Clinical studies in humans also agree that estrogen do s have an effect on body weight. A 
cross-sectional study and a prospective, double blind, placebo-controlled study showed an 
increase in body mass index (BMI) and body weight, respectively, as menopause transitioned 
(Burger et al., 1995; Pepi, 1995). Bjorkelund et al (1996) also reported an increase in waist-to-
hip ratio between the pre- and postmenopausal periods in their longitudinal study. This increase 
in body weight, and particularly body fat, has been s en by many (Hunter et al., 1996; Zamboni 
et al., 1992; Kontani et al., 1994). Stevenson et al (1994) demonstrated that hormone 
replacement therapy (HRT) with estradiol in postmenopausal women prevented abdominal 
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weight gain, and Dellongeville t al (1995) described a lowering of BMI once treated with HRT. 
Another study with newly postmenopausal women found that those on HRT had no significant 
weight gain, while those on simply a calcium supplement had a significant increase in body fat 
weight, with most of the weight gain occurring in the trunk and the arms (Gambacciani et al., 
1996).  
 Not only is there clear evidence of fat accumulation with the onset of menopause, some 
believe that there is in fact a loss of fat free mass. Poehlman et al (1995) noted an average 3 kg 
loss of fat-free mass in women between their premenopausal and postmenopausal periods in a 
longitudinal study. Others suggest that there is predominantly a loss in skeletal muscle mass 
(Poehlman et al., 1993; Aloia et al., 1991). Toth et al (2000), however, did not see this similar 
loss in fat free mass. 
 Menopause and loss of estrogen production may also be associated with type 2 diabetes, 
possibly due to weight gain. Considering estrogen’s reversal effect on fat accumulation in former 
studies, research looked at its possible role in treatment of diabetes. Simply knocking out the 
estrogen receptor resulted in insulin resistance and glucose intolerance (Heine et al., 2000). In 
one study, estrogen treatment was shown to increase cell surface insulin receptor number in 
ovariectomized rats, which increased insulin binding a d receptor-mediated insulin degradation 
(Krakower, Meier, & Kissebah, 1993). Geisler et al (2002) reported inhibition of both weight 
gain and hyperglycemia in a male mouse model prone t  hyperglycemia when treated with 
estradiol. In postmenopausal women, estradiol treatm n  increased secretion of pancreatic insulin 
and decreased insulin resistance (Stevenson et al., 1994). In men unable to produce estrogen, 
insulin resistance ensued (Grumbach & Auchus, 1999).  
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 Cardiovascular complications are also a concern with the onset of menopause and the 
central body obesity that results. Stevenson et al (1994) suggest that HRT in postmenopausal 
women can reduce coronary heart disease by 50%. In another study, hyperlipidemia was shown 
to result in men with estrogen insufficiency (Grumbach & Auchus, 1999).  
 The means by which estrogen plays a role in energy homeostasis may work via various 
hormones. In the rat model, ovariectomy was shown to decrease mRNA levels and serum 
concentrations of leptin (Shimizu et al., 1997), which signals to the brain decreased fat mass and 
results in a hyperphagic state as well as decreased en rgy expenditure (Mantzoros, 1999). Once 
again, estradiol treatment reversed these effects (Shimizu et al., 1997). Ainslie t al (2001), 
however, did not find decreased secretion of leptin in ovariectomized rats, and Pelleymounter et 
al (1999) also reported no alteration in leptin levels with either ovariectomy or estradiol 
treatment. Besides leptin, lack of estrogen in the ovariectomized rat model has been shown to 
increase hypothalamic neuropeptide Y (NPY) mRNA expr ssion, which stimulates food intake 
and may have a role in excess fat accumulation as well (Shimizu et al., 1996; Ainslie et al., 
1999).  
 Considerable evidence has shown that estrogen indeed plays a role in energy metabolism, 
and disruption of estrogen synthesis has been shown t  result in fat accumulation. Data reports 
that this weight gain can be blunted or even reversed if estrogen is once again provided, 
suggesting that it is the deficiency of estrogen that is responsible for the weight gain during the 
postmenopausal period.  
HIGH FAT DIETS 
 Much attention regarding the amount of fat in the diet has been received lately in relation 
to weight gain and the prevalence of obesity. High fat diets are often to blame for inducing 
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obesity. Fat has a higher energy density relative to the other macronutrients, and is considered 
more palatable, which can easily lead people to consume more. Overall, this combination can 
lead to a greater energy intake relative to output (Seidell, 1998; Willet, 1998). A “westernized” 
diet that is highly processed, high in fat, cholesterol, refined sugar, and alcohol, and low in fruits 
and vegetables has been adopted in the United States and most Western  countries (Cordain et 
al., 2005). Although dietary fat cannot be the sole responsibility of the obesity epidemic, it is a 
major concern in today’s unbalanced diet. And although the body has regulatory systems that 
attempt to maintain body weight, Woods et al (2003) explain, “that when individuals are 
exposed, on a chronic basis, to a higher mean levelof dietary fat, the otherwise incredibly robust 
negative feedback system that regulates body fat decreases. More fat is stored and the individual 
moves along the scale toward obesity.” Reducing fat int ke is a difficult task, especially since fat 
is often used in foods for its palatability and ability to increase shelf life.  
 Weight gain and fat accumulation are the most commn associations with diets high in 
fat, but there are certainly other adverse health effects that are linked to high fat diets. 
Epidemiologic studies have shown that diets high in total and saturated fat have been associated 
with fasting hyperinsulinemia (Maron, Fair, & Haskell, 1991; Parker et al., 1993; Mayer, 
Newman, Quesenberry, & Selby, 1993) and have been shown to cause insulin resistance in rats 
(Storlein et al., 1986). As explained earlier, diets high in dietary fiber control insulin release by 
reducing the amount of secreted GIP, and RS is likely to have the same effects to counter this 
with high fat diets.  
 Epidemiologic data support the relationship between higher fat consumption and weight 
gain. The observation of migrants who have adopted th  western diet and the concomitant weight 
gain and disease states that are not normally seen in their native countries has further elucidated 
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the consequences of this eating pattern. The prevalence of obesity was reported to be three times 
as high in Japanese men living in California relative to their Japan-inhabited counterparts (Kato 
et al., 1973). The Pima Indians are another prime example of the deleterious effects of a 
westernized diet that is cheap, palatable, and high in fat (Schrauwen & Westerterp, 2000). Those 
that still live in Mexico maintain their traditional eating habits and lifestyle, while those living in 
Arizona are exposed to the convenience of more processed foods high in refined sugars and fat, 
and less physically-active occupations. The latter group now has a high prevalence of obesity 
and type 2 diabetes from their exposure to this enviro ment (Esparza et al., 2000). In a 
longitudinal analysis, Klesges et al (1992) reported that women with higher fat intake w re 
related to higher weight gain.  
Animal models and clinical trials have associated higher fat diets with weight gain and fat 
accumulation. When rats were given free access to a high fat diet, they became obese compared 
to those on a diet with the same composition except for less fat (Woods et al., 2003). In a study 
by Lissner et al (1987), women fed a high fat diet (45-50%) gained weight relative to a medium 
fat diet (30-35%), and those fed a low fat diet (15-20%) experienced weight loss. In another 
study by Jeffery et al (1995) comparing fat restriction with energy restriction, results concluded 
that a low fat diet had similar weight loss but better compliance among subjects. Higher fat 
intake and weight gain or increased adiposity has been supported by others as well (Tremblay, 
Plourde, Despres, & Bouchard, 1989; Tucker & Kano, 1992). 
 The relationship between high fat diets and the prevalence of obesity has been observed 
for quite some time. The extreme conversion into an industrialized society has not permitted our 
genetics to adjust to all it entails, including lifestyle and eating habits (Cordain et al., 2005). In 
addition to obesity, high fat diets are related to an assortment of other co-morbidities including 
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heart disease and type 2 diabetes. The amount of fat alone is not only important to a healthy 
lifestyle, but the type of fat should also be considered, with more effort in consuming sources of 
unsaturated fatty acids and less intake of saturated nd trans fats (Willet, 1998; Cordain et al., 
2005). It is imperative to find ways to treat overwight and obesity in an effective method that 

















 For both studies, a 2x2 factorial design was used to examine the effects of resistant starch 
on the body weight, body fat, food intake , peptide-YY (PYY) levels, and glucagon-like peptide-
1 (GLP-1) levels in rats. 
Study 1. The effects of resistant starch were compared in rats fed a high fat diet (44.8% 
of energy, 22% fat w/w) to those fed a low fat diet (17% of energy, 7% fat w/w). Half of the rats 
fed the high fat diet (HF) were assigned to a diet h gh in resistant starch (RS), and half were 
assigned to an energy control diet (EC). Half of the rats fed the low fat diet were assigned to a 
diet high in resistant starch, and half were assigned to an energy control diet (Table 3.1).  
Study 2.  An endocrine model of obesity, ovariectomy, was used to test the effects of 
resistant starch. To control for the effects of surgery a sham surgery arm of the 2 X 2 factorial 
was used. Half of the ovariectomized and sham rats were assigned to a diet high in RS, and half 
were assigned to an EC diet (Table 3.2).  
 
 
Table 3.1 2x2 Factorial Design, Study 1 (n=40) 
 FAT 
STARCH HF Diet LF Diet 
EC Diet 10 10 
RS Diet 10 10 
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Table 3.2 2x2 Factorial Design, Study 2 (n=40) 
 SURGERY 
STARCH OVX Rats SH Rats 
EC Diet 10 10 





 For both studies, rats were maintained on a 12:12 hour light/dark cycle that was 
illuminated at 7AM. Water and powdered diet were avail ble ad libitum during the experiment. 
All of the diets were a modification of the American Institute of Nutrition-93 Growing diet 
(AIN-93G) for growing rats. 
 Study 1. Forty, 7 week old male Sprague-Dawley rats were used.  
Study 2. Forty female Sprague-Dawley rats were used. Twenty of the rats underwent 
surgery to remove the ovaries, and 20 underwent a sham operation to equate the physiological 
stress that results from ovariectomy surgery. The surgery was performed on the rats at 10 weeks 
age by the supplier, Harlan (Indianapolis, IN).  
HOUSING 
 All animals were housed in stainless steel cages with ire mesh bottoms to 
account for food spillage, and with wire mesh fronts i  order to view the animals. The powdered 
diet was placed in glass food jars by the experimenter, and secured by a wire spring that attached 
to the wire mesh front of the cage. Water was availble via a water nozzle at the back of the cage 
that released water when it is pushed on. Cardboard sheets were set under each animal’s cage to 




 Study 1. 
 Diet Preparation. To prepare each diet, macronutrients (without fat) were measured and 
combined in a large mixing bowl. The macronutrients were mixed for 10 minutes. 
Micronutrients were then measured, combined in a smll ixing bowl with food coloring if 
necessary, and mixed for 10 minutes. One scoop of the macro mix was then added to the micro 
mix in the small mixing bowl, and mixed for 10 minutes. Then this micro mix was added to the 
large mixing bowl and mixed for 10 minutes to evenly distribute the ingredients. Oil or oil/solid 
fat was then measured and added to the mix, and mixed for 30 minutes. The diet was stored in 
labeled containers in refrigerators and freezers. The label included diet type, date of preparation, 
and researcher’s name. Ten kilogram batches were mad at a time. 
 The rats were randomly assigned to a low fat control diet, low fat resistant starch diet, 
high fat control diet, or high fat resistant starch diet. Resistant starch was used in the form of Hi-
Maize® cornstarch (National Starch, Bridgewater, NJ). The compositions of the diets are listed 
in Table 3.3. The energy breakdown of the diets is li ted in 3.4. 
Table 3.3. Diet Composition Table for LFEC, LFRS, HFEC, HFRS to make a 10 kg Batch 
INGREDIENTS LFEC LFRS HFEC HFRS 
Macro Mix     
Amioca (g) 5347 1500 3847 - 
Hi-Maize (g) -  4807 -  4807 
Sucrose (g) 500 500 500 500 




Cellulose (g) 960 - 960 - 
Micro Mix     
Mineral Mix (g) 350 350 350 350 
Vitamin Mix (g) 100 100 100 100 
Choline Chloride (g) 13 13 13 13 
L – Cystine (g) 30 30 30 30 
Oil Mix     
Vegetable Oil (g) 700 700 1000 1000 
Lard (g)   1200 1200 
BHT (g) 0.140 0.140 0.140 0.140 
TOTAL 10000 g 10000g 10000g 10000g 
 
Table 3.4. Caloric Composition of the LFEC, LFRS, HFEC, and HFRS diets as % (g/100g) 
 Nutrient LFEC LFRS HFEC HFRS 
Protein 21 21 21 21 
Total Carbohydrates 61.9 61.9 61.9 61.9 
Fat 17.1 17.1 44.8 44.8 
Kcal/g of Food 3.5 3.5 4.2 4.2 
 
Week 1: Acclimation Period. All animals were fed a low fat control diet for one week to 
become acclimated to the powdered diet and environment. The weight of the animal, the weight 
of the empty food jar, the weight of the full food jar, and the food spillage were measured three 
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times a week (Monday, Wednesday, and Friday) for each animal. After measurements were 
taken for empty food jar weights, the food jars were refilled and full jar weight was recorded.  
 Week 2: Group Assignment. After the acclimation period, the animals’ weights were 
used to determine group assignment. The animals’ weights were put into ascending order and 
then ordered into four blocks of 10 replicates. The animals were assigned to one of four 
treatment groups by choosing one from each block at a time.  The result was that the average 
weight for each group was within one-tenth of a gram of one another.  
Weeks 2 through 14: Treatment. Throughout the experiment, the animals’ weights, the 
empty food jar weights, the full food jar weights, and the food spillage were measured every 
Monday, Wednesday, and Friday beginning between 12PM- M. Empty food jars consisted of 
the leftover food in the food jar. Full food jar consisted of the weight of the food jar once it was 
refilled with the powdered diet. Every Monday, food jars were switched for clean food jars, and 
any leftover diet in the food jar was thrown out for resh diet. Throughout the experimental 
period, animals were switched to new cages every two weeks for sanitary reasons. The animals 
were fed on their assigned diets for 12 weeks.  Body fat of the animals was measured using the 
nuclear magnetic resonance (NMR) method at the beginning, middle and end of the treatment 
period.  
Week 15: Sacrifice. The animals were sacrificed via decapitation. Due to the large 
number of animals, the sacrifice took place over 2 days between days, spaced 2 days apart. 
Tissues that were collected included blood samples, brain, scrapings of the top cellular layer of 
the cecum, cecal content samples, peri-renal fat, epididymal fat, and retroperitoneal fat. 
Measurements that were taken included the entire gastrointestinal tract weight with contents, full 
cecum weight, empty cecum weight, peri-renal fat weight, epididymal fat weight, and 
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retroperitoneal fat weight. The ceca were gently rinsed with a saline solution to remove any 
contents before empty ceca weights were taken. Cecal contents were stored in the freezer. Brains 
were frozen on dry ice, blood was kept cold on ice before plasma separated by centrifugation and 
stored in the freezer, and cecal scrapings were stod in foil and frozen in liquid nitrogen during 
the sacrifice until the tissues could be stored in the freezer.  
Cecal contents were used to analyze pH.  
Study 2. 
 Diet Preparation. The same diet preparation procedure used in Study 1 was also used in 
Study 2. 
 The rats were randomly assigned to either the energy control diet or resistant starch diet 
from the ovariectomized or sham surgery groups. Thecompositions of the diets are listed in 
Table 3.5. The energy breakdown of the diets is listed in Table 3.6. 
Table 3.5. Diet Composition Table for EC and RS diet to make a 10 kg Batch 
INGREDIENTS EC RS 
Macro Mix   
Amioca (g) 4245 - 
Hi-Maize (g) -  5307  
Sucrose (g) 1000 1000 
Casein (g) 2000 2000 
Cellulose (g) 1562 500 
Micro Mix   




Vitamin Mix (g) 100 100 
Choline Chloride (g) 13 13 
L – Cystine (g) 30 30 
Oil Mix   
Vegetable Oil (g) 700 700 
BHT (g) 0.140 0.140 
TOTAL 10000g 10000g 
 
 
Table 3.6. Caloric Composition of the EC and RS diets as % (g/100g) 
  EC RS 
Nutrient %(g/100g) %(g/100g) 
Protein 21 21 
Total Carbohydrates 61.9 61.9 
Fat 17.1 17.1 
Kcal/g of Food 3.3 3.3 
 
Weeks 1 through 6: Acclimation Period. All animals were fed a control diet for four 
weeks to become acclimated to the powdered diet and environment. The weight of the animal, 
the weight of the empty food jar, the weight of the full food jar, and the food spillage were 
measured three times a week (Monday, Wednesday, and Friday) for each animal. After 
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measurements were taken for empty food jar weights, t e food jars were refilled and full jar 
weight was recorded.  
Week 7: Group Assignment. After the acclimation period, the animals’ weights were 
used to determine group assignment. The animals’ weights were put into ascending order within 
ovariectomized and sham surgery groups.  The weights were then ordered into two blocks of 10 
replicates per surgery type. The animals were assigned to one of four treatment groups by 
choosing one from each block at a time.  The result was that the average weight for each of the 
two ovariectomized groups was within one-tenth of a gr m of one another; and the same for the 
two sham groups.  
Week 7 through 19: Treatment. Throughout the experiment, the animals’ weights, the 
empty food jar weights, the full food jar weights, and the food spillage were measured every 
Monday, Wednesday, and Friday beginning between 10AM-12PM. Empty food jars consisted of 
the leftover food in the food jar. Full food jar consisted of the weight of the food jar once it was 
refilled with the powdered diet. Every Friday, food jars were switched for clean food jars, and 
any leftover diet in the food jar was thrown out for resh diet. Throughout the experimental 
period, animals were switched to new cages every two weeks for sanitary reasons. The animals 
were fed on their assigned diets for 12 weeks.  
Body fat of the animals was measured using the NMR method at the beginning, middle 
and end of the treatment period.  
Week 19: Sacrifice. The animals were sacrificed via decapitation. Due to the large 
number of animals, the sacrifice took place on two consecutive days. Tissues that were collected 
include blood samples, brain, cecal scrapings, cecal samples, peri-renal fat, epididymal fat, and 
retroperitoneal fat. Measurements that were taken included entire gastrointestinal tract weight, 
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small intestine weight, full cecum weight, empty cecum weight, perirenal fat weight, ovarian fat 
weight, mesentaeric fat weight, and retroperitoneal fat weight. The ceca were gently rinsed with 
a saline solution to remove any cecal contents before empty ceca weights were taken. Cecal 
contents were stored in the freezer. Brains were frozen on dry ice, blood was kept cold on ice 
before plasma separated by centrifugation and stored in the freezer, and cecal scrapings were 
stored in foil and frozen in liquid nitrogen during the sacrifice until the tissues could be stored in 
the freezer. 
 For analysis of tissues, the animals’ brains were r moved from the freezer to isolate the 
arcuate nucleus of the hypothalamus and extract the total RNA from the arcuate.  Then the the 
mRNA expression for proopiomelanocortin in the arcute nucleus of the hypothalamus was 
determined releative to the housekeeping gene cyclophilin. The cecal scrapings were used to 
analyze the mRNA expressions for PYY and GLP-1. 
CONSTRUCTS AND VARIABLES 
 Weight of Rats. Animals were measured in a bucket on a balance that was tared to zero 
before the animal was put in. The weight was measured in grams, and rounded to the nearest 
gram.  
 PYY Levels and GLP-1 Levels. Total peptide YY (PYY), total glucagon-like-peptide-1 
(GLP-1), and active GLP-1 were assayed with radioimmunoassay kits from Millipore (St. 
Charles, MO).  
 Amount of Food Consumption. Food consumption was calcul ted by subtracting the 
empty food jar weight and food spillage weight of the current day’s measurement from the full 
food jar weight of the previous day’s measurement. Empty food jar weights were measured on a 
balance, and measured in grams rounded to the nearest gram. The food jars were then refilled 
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with the appropriate diet. Full food jar weights were measured on the balance in grams, rounding 
to the nearest gram. Food spillage was accounted for by removing any feces from the cardboard 
sheet, and weighing the leftover food spillage. The spillage was measured in a weigh boat that 
was tared to zero before the food was put in. Total f od consumed for each rat was measured 
every Monday, Wednesday, and Friday.  
 Cecal Content pH.  The pH of the cecal contents wadetermined by homogenizing 
thawed cecal contents in distilled water (0.5 g wet sample to 5 ml water), and the pH was 
measured using a combination electrode. The samples were acidified with 1 ml of a 25 % (w/w) 
solution of meta-phosphoric acid that contained 2g/l of 2-ethyl-butyric acid as an internal 
standard for the short chain fatty acid contents. Solids in the homogenized samples were 
separated by centrifugation. Short chain fatty acids in the effluent were analyzed using gas-liquid 
chromatography.  
 Body Fat. Total body fat was determined using the NMR method. One at a time, each 
animal was inserted into Bruker’s minispec Lean/Fat Analyzer for measurement. Each animal 
was measured twice, and the average of the two body fat percentages was used. NMR 
measurement was taken three times during each study: once before treatment started, once six 
weeks after treatment began, and once before sacrifice. Upon sacrifice, abdominal fat pad 
weights were also collected and measured.  
STATISTICAL ANALYSIS 
 Data were analyzed using the Statistical Analysis Sy tem (SAS) statistical software 
package version 9.1. A 2x2 factorial was performed for all measurements. Results were 







Cumulative food intake was higher for LF rats relative to HF rats (LFEC, 593; LFRS, 
612; HFEC, 499; HFRS, 482 ± 14.85 grams, p<0.0001) (Fig. 4.1), but energy intake remained 
the same among all treatment groups (LFEC, 2077; LFRS, 2142; HFEC, 2085; HFRS, 2017 ± 
56.3 kJ) (Table 4.1). HF rats did have an increase in body weight compared to LF rats (LFEC, 
366; LFRS, 383; HFEC, 397; HFRS, 402 ± 7.84 grams, p<0.0027) (Table 2). Disemboweled 
body weight was higher in the HF rats (LFEC, 351; LFRS, 357; HFEC, 383; HFRS, 387 ± 6.05 
grams) compared to LF rats (p<0.0001) (Table 2). Full cecum (p<0.0001) and empty cecum 
weights (p<0.0001) were higher in RS rats compared to EC rats, and higher in LF rats compared 
to HF rats (Table 4.1), with LFRS rats having significantly higher full and empty cecum weights 
relative to the other groups. This resulted in a significant fat x diet interaction. Epididymal fat 
(p<0.0001), abdominal fat (p<0.0001), perirenal fat (p<0.0003), and the total fat (LFEC, 8.33; 
LFRS, 8.34; HFEC, 11.43; HFRS, 12.59 ± 0.66 grams, p<0.0001) were also higher in the HF rats 
compared to the LF rats (Table 4.1). Plasma PYY was higher in RS rats compared to EC rats 
(LFEC, 132.6; LFRS, 302.4; HFEC, 118.2; HFRS, 141.7 ± 15.3) (Fig 4.2). RS rats had a lower 
cecal contents pH value compared to the EC rats (p<0.0001), and LF rats had a lower pH than 
HF rats (p<0.0001). This resulted in a significant fat x diet interaction, with LFRS rats having the 
lowest pH of cecal contents (LFEC, 8.41; LFRS, 6.67; HFEC 8.23; HFRS, 8.32 ± 0.08) (Fig 4.3).  
STUDY 2  
In the pre-treatment period, OVX rats consumed more en rgy (OVX, 2447; SH, 2122 ± 




Fig 4.1. Average daily food intake for HF/LF study 
 
Table 4.1. Measurements from HF/LF study according to Fat (low fat [LF] and high fat 
[HF]) and Diet (energy control [EC] and resistant starch [RS]) as the independent variables 
Dependent Variable LFEC LFRS HFEC HFRS SEM Fat Starch Interaction 
Beginning BW (g) 248 248 248 248 3 NS NS NS 
Final BW (g) 366 383 397 402 8 0.0027 NS NS 
Disemboweled BW (g) 351 357 383 387 6 0.0001 NS NS 
Full Cecum Weight (g) 3 13.9 2.9 3.5 0.3 0.0001 0.00 1 0.0001 
Empty Cecum Weight (g) 0.6 2 0.6 0.8 0.05 0.0001 0.00 1 0.0001 
Epididymal Fat (g) 4.3 4.4 6.1 6.3 0.3 0.0001 NS NS 
Abdominal Fat (g) 2.7 2.8 3.7 4.4 0.3 0.0001 NS NS 
Perirenal Fat (g) 1.3 1.2 1.6 1.9 0.1 0.0003 NS NS 
Total Fat Pads (g) 8.3 8.3 11.4 12.6 0.7 0.0001 NS NS 





Fig 4.2. Plasma PYY concentration for HF/LF study 
 
 





32.14 kJ, p<0.0001) and more food than sham rats (OVX, 748; SH, 649 ± 9.82 grams, p<0.0001) 
(Table 3). Body weight change during the pre-treatment period was significantly greater for 
OVX rats than sham rats (OVX, 112; SH, 44 ± 2.29 grams, p<0.0001) (Table 4.2). During the 
treatment period, energy intake was higher in RS rats compared to EC rats (p<0.0029) (OVEC, 
4640; OVRS, 4856; SHEC, 4473; SHRS, 4857 ± 93.83) (Table 4.3). Food intake was also higher 
in RS rats compared to EC rats (p<0.0029) (OVEC, 1419; OVRS, 1485; SHEC, 1368; SHRS, 
1485 ± 28.7) (Fig 4.4). Body weight was higher only in OVX rats relative to sham rats 
(p<0.0001) (OVEC, 349; OVRS, 342; SHEC, 284; SHRS, 282 ± 5.6), and so was disemboweled 
body weight (p<0.0001). But disemboweled body weight was also higher in EC rats compared to 
RS rats (p<0.06) (OVEC, 332; OVRS, 320; SHEC, 268; SHRS, 260 ± 5.2) (Table 4.3). Full total 
gastrointestinal weight (p<0.0001), full cecum weight (p<0.0001), and full small intestine weight 
(p<0.0.0349) were higher in RS rats relative to EC rats (Table 4.3). Mesenteric fat (p<0.0016), 
ovarian fat (p<0.0405), perirenal fat (p<0.0208), retroperitoneal fat (p<0.0112) (Table 4.3), and 
the total fat pad weights (p<0.0065) (Fig 5) were all lower in the RS rats relative to EC rats. 
Plasma PYY levels were higher in the sham group fed RS (OVEC, 42.4; OVRS, 34; SHEC, 
34.7; SHRS, 53.3 ± 3.2). OVX rats fed RS, however, had lower total PYY levels (Fig 4.6). This 
resulted in a significant diet x surgery interaction.  Diet had no effect on plasma GLP-1 levels 







Table 4.2. Measurements according to surgery (ovariectomy [OVX] and sham [SH]) after 6 
week recovery period and before diet treatments 
Dependent Variable OVX SH SEM Surgery 
Beginning BW (g) 208 197 1.8 0.0001 
BW after 6 Weeks (g) 346 283 3.9 0.0001 
Fat (g) 54.3 39.8 0.7 0.0001 
Fat/BW (%) 16.8 16.3 0.2 NS 
Energy Intake (kcal) 1452 1427 23 NS 
Weight Gain (g) 116 46 2.3 0.0001 
Energy efficiency (g/kcal) 8.0 3.3 0.2 0.0001 
 
 
Fig 4.4. Cumulative food intake for OVX/SH study 
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Table 4.3. Measurements for 13 week study with Diet(energy control [EC] and resistant starch 
[RS]) and surgery (ovariectomy [OVX] and sham [SH]) as the independent variables 
Dependent  Variable ECOV RSOV ECSH RSSH SEM Diet Surgery Interaction 
Beginning BW (g) 322 326 245 242 4 NS 0.0001 NS 
Beginning Fat (g) 54.3 54.4 39.8 39.7 1 NS 0.0001 NS 
Beginning Fat/BW (%) 16.8 16.7 16.3 16.4 0.3 NS NS NS 
Disemboweled BW (g) 332 320 268 260 5 0.06 0.0001 NS 
Full GI Tract (g) 17.3 22.3 16.0 20.3 0.9 0.001 0.08 NS 
Full Small Intestine (g) 9.8 10.2 9.4 10.7 0.4 0.04 NS NS 
Full Large Intestine (g) 7.5 12.2 6.2 9.6 0.7 0.0001 0.006 NS 
Mesenteric Fat (g) 3.1 2.5 2.8 2 0.2 0.0016 0.03 NS 
Ovarian Fat (g) 5.1 4.2 4.5 3.4 0.4 0.04 NS NS 
Perirenal Fat (g) 1.9 1.4 1.4 1.1 0.2 0.2 0.02 NS 
Retroperitineal Fat (g) 2.2 1.7 1.3 1.1 0.1 0.01 0.00 1 NS 
Total Fat Pads(g) 12.3 9.9 10 7.6 0.8 0.007 0.009 NS 































 Dietary resistant starch is a fermentable fiber that resists digestion in the gut. As a 
component of the diet, its indigestible quality result  in dilution of the metabolizable energy of 
the diet, fecal bulking comparable to non-fermentable fiber, and fermentation in the colon to 
SCFAs with a subsequent increase in PYY and GLP-1 expression in the gut (Nugent, 2005; 
Keenan et al., 2006; Zhou et al., 2006). Energy dilution has been considered a treatment 
possibility for obesity if a person consumes a certain volume of food as opposed to a certain 
amount of energy (Rolls et al., 1998; Willet, 1998), thus displacing extra calories with 
indigestible matter (Howarth, Saltzman, & Roberts, 2001). The gut neuropeptides PYY and 
GLP-1 have both been reported to decrease food intake (Batterham et al., 2002; Batterham et al., 
2003; Strader & Woods, 2005). It is through these mechanisms that RS is proposed to aid in 
reduction of body fat and weight gain.  RS has been reported to reduce fat pad weight (De 
Deckere et al., 1993; Lerer-Metzger et al., 1996; Kabir et al., 1998a) and lower abdominal fat 
(Keenan et al., 2006a). 
 In the first study we examined the effects of RS in a high fat diet on weight, body fat, 
fermentation, and gut signaling. In the second study we examined the effects of RS in an 
ovariectomized rat model of obesity on weight, body fat, fermentation, and gut signaling. RS has 
been previously demonstrated to decrease body weight and adipose tissue (De Deckere et al., 
2003, Keenan et al., 2006a) and increase gene expression of PYY and proglucagon, the gene that 
encodes GLP-1 (Zhou et al., 2006).  
 In the first study, we found that rats fed the HF diet ad libitum did have an increase in 
body weight over the treatment period. RS, however, did not reduce body weight or body fat in 
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either the HF or LF rats. Disemboweled body weight was higher in HF rats relative to LF rats. 
Cumulative food intake was also higher for LF rats compared to HF rats to compensate for the 
decreased energy density due to the lowered amount of fa in the diet. Energy intake remained 
the same for all treatment groups. Epididymal, abdominal, perirenal, and total fat pads were 
higher in HF rats compared to LF rats. However, RS was not effective in reducing body fat. This 
is not consistent with the study performed by Keenan et al (2006a) when fed a LF diet.  
Both full and empty cecum weights were, however, higher in RS rats compared to EC 
rats. The presence of RS in the diet also lowered th  pH of cecal contents in the LF diet, resulting 
in a significant diet x surgery interaction. These results are consistent with previous studies 
regarding the effects of RS on fermentation (Nugent, 2005; Keenan et al., 2006a), although RS 
was not effective in lowering pH in the HF group. Plasma PYY levels were also found to be 
higher in the RS rats, which has been attributed to the fermentation of RS in the colon (Keenan et 
al., 2006a; Zhou et al., 2006). 
 In the second study, both OVX and sham rats were put on a control diet for six weeks to 
allow OVX rats to gain weight. During this pre-treatment period, OVX consumed more energy 
and food, and gained more weight than sham rats. After six weeks, the rats were put on their 
respective diet treatments. During the treatment period, both energy and food intake were higher 
in RS rats compared to EC rats. By the end of the sudy, body weight was still higher in OVX 
rats relative to sham rats. RS rats did have lower disemboweled body weights compared to EC 
rats, although this only approached statistical significance (p<0.06). However, mesenteric, 
ovarian, perirenal, retroperitineal, and total fat p ds were all lower in RS rats compared to EC 
rats. Small intestine weight, cecum weight, and total gastrointestinal weight were all higher in 
RS rats relative to EC rats. Lowered disemboweled bo y weight, lowered fat pads, and greater 
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intestinal weights in RS rats were also seen in a previous study by Keenan et al (2006a). This 
once again reinforces the fact that RS increases fermentation and lowers body fat in the 
endocrine obese model and those fed a low-fat diet.  
 Unlike the previous study, plasma PYY levels were only increased in sham rats fed RS 
and not OVX rats fed RS. The presence of RS also had no effect on GLP-1. Both Zhou et al and 
Keenan et al reported an increase in GLP-1 and PYY levels, and increased proglucagon and 
PYY gene expression, attributing these gut peptides as to at least one mechanism of body fat 
reduction.  
 Both studies performed here were to examine the effects of RS on obese models. The rats 
in the first study were fed a high fat diet to model a more “westernized diet” to induce obesity, 
and the rats in the second study were ovariectomized to induce obesity. RS was not effective in 
lowering either weight or body fat in the high fat diet or low fat diet. The effect of RS on a high 
fat diet (44.8% of energy, 22% fat w/w) has not been tested before, but RS has been shown to 
reduce body fat in a low fat diet (17.1% of energy, 7% fat w/w). We did not observe this even in 
our low fat diet. A possibility for its ineffectiveness on the low fat diet in this study may be 
attributed to the lowered amount of sucrose in the diet. In the study by Keenan et al (2006a) and 
another by Shen et al (2008), 100g of sucrose/kg of diet was used, whereas only 50g of 
sucrose/kg of diet was used in this study. This lowered amount may have affected the palatability 
of the low fat diet, which is already low in fat, and rats may not have consumed enough RS to be 
effective.  We compared body weight, disemboweled bo y weight, and body fat between our rats 
and Shen’s rats to evaluate how the difference in the amount of sugar effected these 
measurements. Our rats and Shen’s rats were ordered from the same company, were the age and 
type of rat, and arrived on the same day.  Upon comparison, Shen’s rats had a greater body 
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weight and disemboweled body weight for both the enrgy control and resistant starch diets 
(Figures 5.1 and 5.2). Body fat was also higher in Shen’s rats relative to our rats (Figure 5.3). 
Both our low fat diet and Shen’s diet had the same ount of fat, but Shen’s diet was prepared 
with 100g sucrose and fed for only 65 days whereas our was prepared with 50g of sucrose and 
fed for 85 days. The combination of a low fat diet and a lowered amount of sugar may have 
compromised food consumption, which ultimately could have affected RS consumption and 
effectiveness or possible fat gain by EC rats. 
In this study, we also noted that full and empty cecum weights were significantly lower in 
the high fat diet than the low fat diet, and pH was significantly higher in the high fat diet 
compared to the low fat diet. These results indicate that fermentation was eliminated with the 
high fat diet. Dietary fat has previously been reported to reduce fermentation of fiber in 
 
 
Fig 5.1. Body weight comparison of rats from Shen’s low fat diet with 100g of sucrose and our 





Fig 5.2. Disemeboweled body weight comparison of rats from Shen’s low fat diet with 100g of 




Fig 5.3. Total fat comparison of rats from Shen’s low fat diet with 100g of sucrose and our low 




ruminants (Macleod & Buchanan Smith, 1972; Devendra & Lewis, 1974; Kowalczyk et al., 
1977). If fat can affect fiber fermentation, then the high fat diet used in this study may also be 
blunting the fermentation of RS. Endogenous lipids have also been shown to complex with the 
amylose chains in RS, which can disrupt RS formation (Eerlingen et al., 1994). If RS is not 
formed, it is most likely being digested just as a st rch, fermentation is not allowed to take place, 
and the subsequent physiological effects of RS are being hindered.  
 In the second study, food and energy intake were higher in the RS rats compared to EC 
rats. Interestingly though, EC rats still had a greater disemboweled body weight. This effect 
appears to be driven by increased energy expenditure because energy intake was lower in EC 
rats. In an unpublished study by Zhou et al (2008), mice fed an RS diet also had a higher 
cumulative food intake and lower body fat, and with a reported lower respiratory exchange ratio 
(RER). This method of measuring respiratory gases i an indication of fat burning. The lower 
RER in RS mice compared to controls indicates greate  f t burning. Higgins et al (2004) also 
reported that replacement of 5.4% of total carbohydrate with RS significantly lowered the 
respiratory quotient (RQ, a measurement of respiratory gases at the cellular level), and increased 
fat oxidation. This moderate level of RS fed in humans also indicates greater fat burning. This 
data suggests that in our studies RS does not decrease food intake, but its role is to increase fat 
burning, which appears to promote its ability to reduce body weight and body fat.  
 Also in the second experiment, lowered disemboweled body weights, lowered fat pads, 
and greater intestinal weights were all observed in the RS rats relative to EC rats, even though 
there was no difference observed in GLP-1 between th  diet treatments, and PYY appeared to be 
effective only in sham rats fed RS. As stated before, it has been previously reported by Keenan et 
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al and Zhou et al that increased gene and protein levels of PYY and GLP-1 are associated with 
consumption of RS. The fact that these two gut hormones were not associated with RS 
consumption, but larger intestinal weights and reduc  body fat were both still seen with RS 
consumption suggests that RS may work through other hormones or another mechanism beyond 
gut signaling. Previous work has presented gene array data demonstrating vast differences in 
expression of the cecal cell genome in rats (Keenan t l., 2006a; Keenan et al., 2006b). Other 
factors possibly involved include other gut hormones, neural, and immune factors.  
 In conclusion, the data from the current study suggests that RS is ineffective in reducing 
body weight and body fat in rats when fed concomitantly with a high fat and low fat diet. These 
results are contrary to previous reports of the association between RS consumption and reduced 
body fat and body weight. It is possible that the high fat diet may blunt the effects of RS 
fermentation. However, RS consumption did indicate that fermentation took place in rats fed the 
low fat diet, although weight gain was too low in rats fed the low fat, RS diet due to due 
decreased sucrose levels. In our second study, adding resistant starch to the diets of OVX rats 
was effective in reducing accretion of abdominal body fat, even though the data did not support 
it was done through gut signaling with PYY and GLP-1 as previously demonstrated. The 
mechanism for this remains to be determined. However, this suggests that dietary resistant starch 
may improve health by reducing body fat in postmenopausal women. Further research 
investigating other possible means by which dietary resistant starch is effective in reducing body 
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A new protocol form must be filled out and submitted to the IACUC: 
 
1) to receive approval to begin experiments/procedures using laboratory animals; 
 
2) if there are changes in major operative procedures in previously approved protocol (the protocol is not 
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As required by the Public Health Service Policy all protocols must be reviewed by the IACUC every three years. The 
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SECTION 1: Investigators 
 
Principal Investigator 
















SECTION 2. Project Title:  
 
The role of PYY and GLP-1 in energy balance with resistant starch fed animals 
 
SECTION 3.  Funding Source:  Is this protocol associated with a grant or contract?  
  Yes        No    
Funding agency: 
NIH 
Grant or contract 
title: 
Dietary Resistant Starch: The role of PYY and GLP-1 in energy 
balance  
  Pending         Funded 
 
SECTION 4.  Investigator’s Statement regarding the assurance for the Humane Care 
and Use 
 of Vertebrate Animals. 
By signing this form, I agree to abide by Pennington Biomedical Research Center’s Policy for 
the Care and Use of Animals.  This project will be in accordance with the NIH “Guide for the 
Care and Use of Laboratory Animals” (except as explained in the accompanying protocol), and 
the PBRC Animal Welfare Assurance on file with the U.S. Public Health Service. I further assure 
the Committee that: 
1) I will abide by all federal, state, and local laws and regulations governing the use of 
animals in teaching and research. 
2) The investigators and technicians are or will be adequately trained to perform the 
research techniques required in these studies. 
3) I will use the fewest number of animals required to produce the appropriate statistical 
power for this study. 




5) For those completing Section 14.2 and 14.3:  I have reviewed the pertinent scientific 
literature and the sources and/or databases as noted in Section 14, and have found 
no valid alternative to any procedures described herein which may cause more than 
momentary pain or distress, whether it is relieved or not. 
Roy Martin 
Professor  
Type Name of Principal Investigator  Title/Rank Date 
  
Principal Investigator Signature  
Jun Zhou Post-Doc  
Type Name of Co-Investigator Title/Rank Date 
  
 Co-Principal Investigator Signature  
Animal housing and veterinary care must be coordinated with Comparative Biology. 
  
Signature of Comparative Biology Representative (required) 
 
SECTION 5. Animal Species: 
 
Species:    Mouse     Rat           Other Strain: C57BL/6J  
Sex:          Male       Female     Either      
Both Weight (or age for rodents): six weeks old 
Source:     Commercial Vendor     PBRC Breeding Colony       Collaborator   
 
Species:    Mouse     Rat           Other Strain: Sprague Dawley 
Sex:          Male       Female     Either      
Both Weight (or age for rodents): eight weeks old  




Species: Mice  Rats  Other 
Number of animals needed:       
Year 1: →200  340       
Year 2: →580             
Year 3: →                 
TOTAL: →780  340       
Maximum # needed at one time: 200  100       
 
SECTION 6. Abstract Plan of Research/Teaching:  In the space below, using non-
technical       terms provide a brief (1 – 2 paragraphs) layman’s description of the 
project.  Include the aim of the study and how this study may benefit human or animal 
health or advance scientific understanding of biological processes. 
 
 
Resistant starch is a dietary carbohydrate that resists digestion in the small intestine 
and is fermented in the large intestine. Our preliminary studies showed that feeding 
resistant starch significantly altered energy balance and decreased body fat in rodents.  
Additionally, resistant starch fed rodents had higher gene expressions for peptide YY 
(PYY) and proglucagon (a precursor of glucagon-like peptide-1, GLP-1) in the gut, and 
higher serum levels of PYY and GLP-1.  PYY and GLP-1 are satiety peptides secreted 
from the gut.  Administration of either PYY or GLP-1 reduces food intake.  Thus, we 
hypothesize that the decreased body fat is due to increased PYY and/or GLP-1 
(PYY/GLP-1) in resistant starch fed animals.  The hypothesis will be tested in three 
specific aims. First, we will block PYY/GLP-1 action to determine if PYY and GLP-1 are 
required for resistant starch to decrease body fat.  This will be achieved by using 
PYY/GLP-1 receptor antagonists or by using the PYY/GLP-1 receptors knock out mice.  
Second, we will investigate if PYY/GLP-1 decrease body fat via visceral nerves or the 
brain. The peripheral sites of action for PYY/GLP-1 will be tested by destroying visceral 
afferent neurons to block signals to the brain.  Finally, we will test if resistant starch 
decreases body fat in robust obese animal models.  A diet-induced obesity model and a 
genetic obese model will be used to see if resistant starch can prevent obesity.  These 
experiments will reveal that PYY and GLP-1 are part of the mechanism of resistant 
starch on reducing body fat.  Thus, a simple dietary intervention can increase levels of 
these peptides and reduce body fat naturally without surgery or pharmaceutical means.  
This dietary approach is potentially of great therapeutic importance in the prevention of 






SECTION 7.  Special Husbandry Requirements:  Do your animals have special 
needs to be addressed by Comparative Biology?   
 
  Yes  No 
 
If yes, please complete each section that is different from the standard of care for rodents. The 
standard of care is: plastic shoebox, corn cob bedding, rodent chow, ≅21-22°C room 
temperature, ≅55% humidity, and tap water. 
TEMPERATURE 
RANGE:   21-22°C room 
temperature   
HUMIDITY:  
 55 (%) 
LIGHT CYCLE (hours light/hours dark) 
12/12 
CAGING 
Type: 1) Shoe boxes 
for breeding mice 
Size:  
single /multi Filter tops required?   Y      N 
BEDDING/LITTER 
Type: corncob and 
nesting material 
Autoclaved?  
  Y    N Changes/week:  3 
CAGING 
Type: 2) appropriate 
SS hanging wire cages 
for  experimental mice 
and rats Size: Single Filter tops required?   Y      N 
BEDDING/LITTER 
Type: pan liners and 
weigh backs 
Autoclaved?  
  Y    N 
Changes/week:  1 
By investigator only* 
WATER 
Sterile:  Y    
 N 
De-ionized:  Y  
N 
Acidified:  Y    
 N 
Tap:  Y     
N 
Other:  
* weigh backs will be changed 3 to 7 times per week by investigator 
when measuring spillage. Pan liners will be changed 1 time per week 
by investigator 
DIET 
Special Feeding Requirements: 
 Investigator will mix custom diets (see table below) and feed 
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experimental animals  
3-7 times per week. 
 Breeder mice will be provided breeder chow by DCB. 
IF USING WIRE BOTTOM CAGES, PLEASE JUSTIFY: 
We will measure food intake in our animals. Hanging wire cages are required so that we can accurately 
account for food spillage. As experiment period could last as long as 12 weeks, a PVC tube will be placed 
in each mouse cage to reduce the stress caused by wire cage.  Breeder pairs will be multi-housed in 
shoeboxes. Prior to due date, males will be removed and either place with an available female or single 
housed in shoe boxes. Females will be singled housed with neonates until weaned. Weanlings will remain 
in shoe boxes until placed in experiments.  
OTHER SPECIAL NEEDS: 
Table 1. Experimental Diet Composition 
Ingredient 
Control 
(g/kg) 30% RS(g/kg) 
High Fat Control 
(g/kg) 
High Fat 27% RS 
(g/kg) 
Casein 200.0 200.0 200.0 200.0 
Sucrose  100.0  100.0  50.0  50.0 
Cornstarch - Amioca® 
 (100% amylopectin) 424.5  384.5  
Cornstarch - Hi-Maize® (high 
amylose)  530.7  480.7 
Cellulose fiber 156.2   50.0 96.2    
Soybean oil  70.0   70.0 100.0 100.0 
Vegetable shortening   120.0 120.0 
Mineral Mix (AIN-93G)  35.0   35.0  35.0   35.0 
Vitamin Mix (AIN-93)  10.0   10.0  10.0   10.0 
Choline Chloride    1.3     1.3    1.3     1.3 
L-Cystine    3.0     3.0    3.0     3.0 
Total  (3.27 kcal/g)  (3.27 kcal/g)  (4.2 kcal/g)  (4.2 kcal/g) 
Protein  22.2% kcal 22.2% kcal 17.2% kcal 17.2% kcal 
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Carbohydrates 59.7% kcal 59.7% kcal 38.1.7% kcal 38.1% kcal 
Fat 18.1% kcal 18.1% kcal 44.8% kcal 44.8% kcal 
SECTION 8.  Hazardous Materials:  Will zoonotic/recombinant agents or hazardous 
chemical agents be PRESENT IN THE ANIMAL ROOM?      
 YES        NO 
If “yes” complete the appropriate section(s) below. 
8.1 Zoonotic/Recombinant Agents:  If zoonotic (infectious to humans) or 
recombinant agents will be used, this protocol request must be submitted to the 
LSU Institutional Biological Recombinant DNA Safety (IBRDS) Committee for 
approval PRIOR TO CONSIDERATION by the IACUC.  Submit copy of the 
IBRDS approval letter to the IACUC Administrator with the animal protocol. 
 
List 
Agent(s):         
 
IBRDS Approval Date:       PBRC Safety Officer:       
 
8.2 Hazardous Chemicals: If hazardous chemical are to be used in the animal 
room, submit the proposal with Appendix A completed, to the Biosafety 
Committee for prior approval.  SOPs for some commonly used materials are 
available on PINE. 
 
List 
Chemical(s):         
 
Biosafety Committee Approval Date:        
 





Will radioisotopes be used in 
animals?     YES        NO 
List Radioisotopes:       
Are you certified by the Radiation Safety 
Committee?       YES        NO 
Where (Room #’s) will radioisotopes be used in animal 
experiments?       
Is this a terminal experiment?  YES        NO 
  
If you have any questions regarding approval of the use of zoonotic/recombinant 
agents, hazardous chemicals, or radioisotopes see the PBRC Safety Office @ 
3-2667. 
 
SECTION 9. Type of Project: (check the appropriate box) 
 TYPE A - Pain or distress will not be induced; animals will only be used for 
injections, collections, or procedures causing nothing more than minor 
discomfort; or will be humanely euthanized prior to induction of pain or distress. 
 TYPE B - Pain or distress will be relieved by appropriate therapy. 
 TYPE C - Drug intervention for pain or distress would interfere with the protocol.  
Specific scientific justification MUST be provided below for Type C protocols.  




SECTION 10.  Summary of Procedures:  Answer each of the following.  If a section is 
not applicable, indicate so by “N/A”.  Your target audience is a faculty member from a 
discipline unrelated to yours.   
 
10.1. Rationale: Explain your rationale for animal use.  Briefly explain why should this 
study be done and what hypothesis/es will be tested? 
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Resistant starch has been used as a dietary carbohydrate in humans.  However, the 
effects of reducing body fat by resistant starch are equivocal due to the complexity of 
human dietary studies.  Using rodents to study the effects of resistant starch will allow 
control of the genetic verities, daily activity and dietary components.  Using knock out 
mice could allow us to study the mechanism of resistant starch on reducing body fat.  
The results of our study will provide the important mechanistic information on how 
resistant starch reduces body fat.  More specifically, if resistant starch reduce body fat 
through increase in secretion of PYY and GLP-1 in the gut. 
 





10.3. Experimental Design:  Provide a concise description of the proposed use of animals.   
This description should allow the IACUC to understand the experimental course of each 
group of animals from its entry into, until the endpoint of the experiment.  A flow chart 
(timeline/sequence), diagram, and/or a table (see note below) indicating animal numbers 
and group assignments are STRONGLY recommended to help the IACUC understand 
what is proposed.  Include experimental procedures and any physical, chemical, or 
biological agents (name, dose, volume, route, and frequency) that may be 
administered.  Details of specific nonsurgical and surgical procedur s should be provided 
in Sections 10.5 and 10.6 respectively.  Form Note:  Due to the difficulty of inserting 
tables and flow charts/diagrams directly into the form consider creating these in Word 
and attaching them to the end of protocol. 
. 
Animal number and timeline for proposed studies is listed below. 
 
Experiment                Animal number                          Year                           Length 
Expt. 1.                      140 SD rats                                    1                            10 days 
Expt. 2                       100 SD rats                                    1                         Six weeks 
Expt. 3                       100 SD rats                                    1                         Six weeks 
Expt. 4                        80 mice                                               2                          12 weeks 
Expt. 5                       100 mice                                        1                          12 weeks 
Breeding mice  
for Expt. 6                  100 mice                                              1                                           
Breeding mice  
for Expt. 7                  100 mice                                              2                                           
Expt. 6                        200 mice                                        2                           12 
weeks 
Expt. 7                        200 mice                                        2                           12 
weeks 
 
Mice and rats are selected because these animals are commonly used for mechanistic studies on 
body weight regulation and energy balance. 
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Experiment 1.  Determine the timing of sample collection. 
       We will feed two groups of SD male rats with either control or resistant starch diet 
for ten days.  At the end of Day 10, the rats will be killed by decapitation at 0, 2, 4, 8, 12, 
16, and 20 hours after the beginning of the dark cycle (ten rats for each time points for 
each group).  The blood, brain and tissues from the gut will be collected from each rat.  
PYY/GLP-1 expression levels in the blood and gut will be measured for each rat.   
 
Experiment 2.  Will injecting both Y2R and GLP-1R antagonists simultaneously in 
rats block the action of both PYY and GLP-1? 
        BIIE0246 is a well-established PYY receptor antagonist and des-His1 Glu9-
exendin-4 is a GLP-1R antagonist.  Both antagonists have been used safely in mice and 
rats at the dosage described below for PYY and GLP-1 functional studies. (1-7)  
Protocol:  One hundred male SD rats will be divided into four weight matched groups: 
(1) saline, (2) BIIE0246 (2.0ug/g body weight, dissolved in 10% DMSO of 
saline i.p.), (3) des-His1 Glu9-exendin-4 (0.23ug/g body weight, dissolved in 
saline, i.p.) and (4) BIIE0246 plus des-His1 Glu9-exendin-4. The injection 
dosages and route will be the same as group (2) and (3).  The injection volume 
for all groups will be 0.2ml/100g body weight and the injection frequency will 
be once per day.  Each injection group will be subdivided into resistant starch 
fed group and control diet fed group (12 rats for each sub-group).  Food intake 
and body weight for each rat will be measured three tim s per week.  At the 
Week 5 after the first injection, all rats will be subjected to measured body fat 
by NMR. The experiment will be terminated six weeks after the start of 
injections.  All rats will be killed by decapitation and their blood, gut, fat 
depots will be collected.  
 
Experiment 3.  Test if PYY & GLP-1 decrease body fat via visceral nerves or the 
brain. 
       Visceral afferent nerves from the gastrointestinal tract carry important signals to the 
brain to control energy balance and body fat.  Thus, we will treat rats with capsaicin to 
destroy visceral afferent neuron and determine if the effects of resistant starch can be 
abolished.  Capsaicin has been used traditionally in study the involvement of visceral 
sensory neurons (1, 8-10).   
Protocol:  One hundred male SD rats, weighing 150-18 g, will be fed the control diet a 
week before sub-grouped into capsaicin or vehicle treatment.  Capsaicin-treatment 
consists of 3 injections of progressively increasing doses over a period of 3 days, 
each under gaseous anesthesia. Rats will be anesthetized with isoflurane and 
doses of 12.5, 30, and 75 mg/kg of capsaicin will be injected ip. The first and 
second injections typically result in temporary respiratory arrest, but breathing 
will restart spontaneously or with the help of gentl  chest massage. The entire 
procedure is carried out under deep Isoflurane anesthesia. Ten minutes after 
resumption of spontaneous breathing, anesthesia is discontinued and animals 
allowed to recover. At the highest dose on the third day, there is usually no 
respiratory arrest. Capsaicin will be dissolved in 10% ethanol/10% Tween 80 and 
sterile saline, and delivered at 0.6 ml/100g for the highest dose. For control 
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treatment, only the vehicle is injected.  Two days after the last capsaicin or 
vehicle treatment, a CCK feeding suppression test will be conducted to confirm 
that capsaicin-sensitive visceral afferents have ben destroyed by capsaicin 
treatment.  One day after the last CCK feeding suppression test, both vehicle 
treated and capsaicin treated rats will be stratified by weight and assigned to 
either the control diet, or the resistant starch diet for a six-week study.  Body 
weight and food intake will be measured three times p r week.  Four days before 
the end of the study, gut transit time will be measured.  At the end of the study, 
the all rats will be killed by decapitation.  The blood, fat depots, gut and brain will 
be collected. 
   CCK feeding suppression test to confirm destroying capsaicin sensitive visceral 
afferents  
                 CCK suppresses food intake via visceral afferents.  Thus, administration of 
exogenous CCK will decrease food intake in control rats but not in capsaicin 
treated rats.  All rats will be fasted overnight.  In the morning, CCK-8 (6ug/kg 
body weight, dissolved in saline) or saline will be injected (i.p. 0.2ml/100g body 
weight) into rats 30 minutes before feeding. One-hour food intake will be 
measured for all rats.  Half the rats of each treatm nt group (capsaicin or vehicle) 
will receive CCK first and the other half will receiv  saline first, with tests 3 days 
apart. Saline treatment will be used to measure normal food intake after an 
overnight fast. CCK treatment should not decrease food intake in capsaicin treated 
rats but should decrease more than 50% food intake in control rats. It there are 
problems with CCK feeding suppression test, a sucrose solutions test will be used 
as an alternative to confirm the destroying capsaicin sensitive visceral afferents.  
   A sucrose solution test to confirm the destroying capsaicin sensitive visceral 
afferents(9) 
                   Three days before the first exposure to sucrose, all rats will be offered daily 
the 10% sucrose solution and allowed to lick for 10 seconds (<0.2ml).  The 
purpose of this training is to eliminate any neophobia toward the new food and 
source but without allowing significant ingestion ad its metabolic consequences.  
By the fourth day, all rats immediately approached the spout and stared drinking.  
The 10% test sucrose solution will be given in the morning between 8:30 and 
11:00am in the bottle attached to the cage front.  I take levels for each rats will be 
measured at 30 minutes and 60 minutes after offering the test sucrose solution. 
Capsaicin treated rats should over consumption sucro e solution when compared 
with controls.   
   Measurement of gut transit time(11, 12): 
                  Each rat will be fed a bolus (2.5 g) of the appropriate experimental diet mixed 
with glass beads (10 mg; diameter range 150-170um) at idnight. The rats will be 
fasted (with free access to water) for 12 h before eeding the boli and all the boli 
should be eaten completely. One hour later, rats will be given free access to food 
again. Six hours after feeding the boli, fecal samples will be collected in glass 
scintillation vials every 2 h up to 30 h after feeding and then every 6 h up to 48 h 
after feeding. The gut transit time will be measured by counting the rate of glass 




Experiment 4:  Determine if resistant starch decreases body fat in a genetically obese mice 
model 
       Intracerebroventricular injection of PYY or GLP-1 have decreased food intake in 
lean and obese mice and their action is additive.  Therefore we will determine if the 
increased plasma levels of both PYY and GLP-1 in resistant starch fed mice are sufficient 
to reduce body fat in ob/ob mice. 
Protocol:  Forty ob/ob (B6.V-Lepob/J) mice and forty of their lean (Lepob heterozygote) 
littermates will be obtained from Jackson Lab and fe the resistant starch or 
control diet for 12 weeks. Body weight and food intake will be measured three 
times per week.  Body fat will be measured at the week 0, 6, 11, when diet 
treatment starts.  At the end of 12 weeks, all mice will be decapitated and blood, 
fat depots will be collected. 
 
Experiment 5: Test if resistant starch decreases body fat in a diet induced obesity 
mice model 
        C57BL/6J mice is susceptible to long-term high fat induced obesity.  Furthermore, it 
has been shown that injections of PYY and GLP-1 reduc  food intake in this model of 
obesity. 
Protocol: one hundred male C57BL/6J mice will be divided into four groups and fed one 
of following four diets. 1) Control diet, 2) resistant starch diet, 3) high fat control 
diet , and 4) high fat resistant starch diet for 12 weeks. Body weight and food 
intake will be measured three times per week.  Body fat will be measured at the 
week 0, 6, 11, when diet treatment starts.  At the end of 12 weeks, all mice will be 
decapitated and blood, fat depots will be collected. 
 
Experiment 6: and 7 will determine if PYY/GLP-1 receptors are required for resistant 
starch to decrease body fat.  We will use Y2R knock out mice and GLP-1R knock out 
mice to test our hypothesis.  GLP-1R knock out mice ar  currently available in PBRC 
comparative biology facility and we have obtained the permission to breed them from Dr. 
Drucker.  The Y2R knock out mice will be obtained from Dr. Herbert Herzog.  As Y2R 
knock out and GLP-1R knock out mice are homozygoteous, all progeny will be used to 
replenish the breeding colony or the experiments. .  However, we will genotyping retired 
breeding mice to confirm the correct genotype.  We will also breeding C57Bl/6J mice at 
the same condition and use these mice as inbreed control for the experiment 6: and 7. 
Breeding strategy. 
Initial breeding will be set up with one male for 3 females in shoebox cages. 
Once pregnancy is evident, female mice will be are single housed in shoe box cages with 
corncob bedding and nesting material until pups are weaned at 21 days. Male and 
female progeny mice will be used to replenish the breeding colony. We expect 6 to 10 
mice per litter, thus allowing for 2 breedings of Generation I to produce a minimum of 
18 females and 6 males. The synchronized timed breeding of these progeny should 
produce adequate numbers of each type for experiments 6 and 7.  If enough Generation 
III progeny are not produced for experiments 6 and 7, then a second breeding of 
Generation II will be initiated. Both male and female mice will be used in these 
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experiments to limit the time needed achieve adequate numbers for all experiments.  A 
small number of the unneeded weanlings will be genotyped to determine if cross 




double knockout mice is possible.  Any correct 
genotyped mice will be held for cross breeding. A separate protocol would be written 
for this. 
  










Generation      I:    Initial breeding group 3 females / one male 
Generation    IIa:   First breeding -groups set up with all progeny  
                      IIb:   Second breeding -groups set up with all progeny  
Generation    III:    breeding from IIa and IIb progeny timed to coincide  
 
Number of animals: 200 




knock out: 1 breeding set  (to produce 150 male or female for Expt. 6 ) 
Male
Female






 knock out: 1 breeding set (to produce 150 male or female for Expt 7) 
  
 Retired breeders and extra weanlings will be used to determine optimum dosages 








Experiment 6  Will injecting the GLP-1R antagonist into Y2R null mice block the 
action of both GLP-1 and 
PYY? 
 
Protocol: Y2R null mice and 
their wild type littermates 
will be obtained from Dr. 
Herbert Herzog.  Forty Y2R 
null mice and forty wild 
type littermates (6-week old 
males and females) will 
have free access to the 
control diet and water for a 
week. Body weight and food 
intake will be measured 
daily.  At the end of one 
week of baseline measurements, the mice in each genotype group will be divided into 
two subgroups:  Saline-injected and GLP-1R antagonist-i jected (des-His1 Glu9-
exendin-4, 2.33ug/0.1ml/10g body weight, dissolved in saline).  The injection (i.p.) will 
be performed daily.  Each injection group will be further subdivided into two subgroups:  
one subgroup will be fed the resistant starch diet and the other group will remain on the 
control diet.  Body weight and food intake will be measured three times per week and 
body fat will be measured every ten days.  The experiment will end one week after the 
body fat becomes significantly lower in the saline-j cted wild type mice fed resistant 
starch as compared with the same genotype mice but fed the control diet.  This 
significantly lower body fat in resistant starch fed mice will occurred within 12 weeks 
from our previous experiment results.  At the end of study, all mice will be killed by 
decapitation and their blood, brain, fat depots, and gut will be collected. 
 
Experiment 7:  Will injecting 
the Y2R antagonist into the 
GLP-1R null mice block the 





































Protocol: The same protocol will be used as in experiment 6, except we will use forty 
GLP-1R null mice and forty wild type littermates (6-week old males and females), and 
the antagonist for Y2R (BIIE0246, 20ug/0.1ml/10g body weight, dissolved in 10% 
DMSO of saline, i.p.) will be injected into these mice.  The GLP-1R knockout mice and 
their wild type littermates will be obtained from Dr. J. Drucker.   
 
10.4. Justification of Animal Numbers: Justify the method used to determine the 
number of animals used for the experiments described in Section 10.3.  This 
could include statistical power analysis, numbers necessary as a continual 
source of tissue harvest for ongoing work, prior experience with similar 
experiments or a limited number for pilot or feasibility studies.  Numbers 
described here should coincide with Sections 5 and 10.3. 
The number of animals used in each experiment is based on a power analysis and on the 
investigator’s experience. The standard deviation of the different measurements 
determines the number of animals to be used in the above experiments and the standard 
deviation varies with different measurements. To provide adequate tissue and blood 
samples for measurements of food intake, blood hormone, and gut peptide/brain 
neuropeptide gene expression, 10-25 rats and 20 to 5 mice are required. Additionally, 
the number of animals needed may be reduced as adequ te information from preliminary 
experiments and breeding numbers are achieved. 
 
10.5. Non-Surgical Procedures:  List and describe each non-surgical procedure to 
which any animal or group of animals may be subjected.  Indicate, where 
appropriate, analgesic, anesthetic, and/or tranquilizing agents that will be used to 
minimize discomfort and pain.   
1. Food intake and body weight measurements: During the defined experimental 
periods within the study protocol, food intakes and body weight will be measured either 
daily or every 2-3 days.  Food and tap water will be provided ad libitum. Food cups with 
experimental diets (table 1) will be prepared and provided by investigator. We 
anticipate very little stress under these situations. 
 
2. Over night fasting: For CCK feeding suppression and gut transit time, the rats will be 
fasted overnight. Food cups will be removed at the start of the dark cycle and returned 
on the following morning and water will be available at all times. 
 
3. Measurement of gut transit time: Each rat will be placed in a metabolism cage with 
free access to water and fasted for 12 hours before feeding a bolus (2.5 g) of the 
appropriate experimental diet mixed with glass beads (10 mg; diameter range 150-
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170um). After one hour and rats will be given free access to food again and will remain 
in the metabolism cages for 48 h after feeding for collection of fecal samples. The size of 
the glass beads should not interfere with digestion or cause stress. The rats will be 
returned to their normal cages after the procedure. 
 
4. Intraperitoneal injection: 
Y2R/GLP-1R antagonists, saline, and CCK will be intraperitoneally injected into animals.  
The injection will be carried by an experienced investigator to reduce the transitional 
discomfort of each animal. 
 
5. Visceral afferent lesion by capsaicin injections: The neurotoxin capsaicin will be i.p. 
injected to rats in experiment 3 to lesion their visceral afferent. The entire procedure is 
carried out under deep Isoflurane anesthesia (induction concentration of 4 -5% 
isoflurane with 20% oxygen and a 1 L/min flow rate, maintenance concentration of 2% 
isoflurane).  The capsaicin will be injected consecutively for three days with increased 
dosages as described in Experiment 3.  The first and second injections typically result in 
temporary respiratory arrest, but breathing will restart spontaneously or with the help 
of gentle chest massage. Ten minutes after resumption of spontaneous breathing, 
anesthesia is discontinued and animal is allowed to recover. 
 
6. Body fat measurement by NMR: We observed difference in body weight for resistant 
starch fed and control fed groups in mice studies.  Body fat will be measured by NMR 
for all animals before the end of experiments.  The mice will be handled daily before 
this measurement to reduce stress effects during this procedure. We anticipate little 
stress effects under such situation. 
 
7. Breeding, Weaning and genotyping: One male and 3 females will be initially obtained 




, and C57Bl/6 
+/+
 
control). We anticipate 2 breedings for the initial females and 1 second generation 
intercross breeding to produce the number of animals required for preliminary testing 
and experiments. Breeding animals will be placed in shoe box cages with corncob 
bedding and nesting material in each cage. One male will be placed with up to three 
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females per shoe box.  Once a female is visibly pregnant, she will be single housed until 
after all pups are weaned. Pups will be weaned at 21 days. Male and females will 
separated and multi-housed in shoeboxes until reaching maturity (six weeks of age). At 
that time they will either be placed in shoeboxes for intercross breeding, or placed in 
stainless steel cages for experimental procedures.  The initial breeding mice will be ear-
punched for identification and tail-clipped for genotyping.  For tail tip collection for 
genotyping, the mouse is restrained briefly and 2-3 mm of the distal tip of the tail is 
rapidly excised with a sterile scalpel blade or sharp scissors.  Before the mouse is 
returned to the cage, the end of tail is touched to a silver nitrate cauterizing stick to 
minimize bleeding and dipped in bupivicaine/lidocaine mixture as a local anesthetic.  
 
 
10.6. Surgical Procedures:   
Does this protocol contain survival surgical procedures?   
 YES (Complete 10.6.a-h)  NO 
Does this protocol contain non-survival surgical procedures? 
 YES (Complete 10.6.a-f)  NO 
 
Does this protocol contain multiple major survival surgeries to occur on an 
individual animal? 
 YES (Must provide scientific justification 
below.)  NO 
 
  
Justification for multiple major surgical procedures:  
 10.6.a  Surgical description:  Describe in detail each surgical procedure.  
Include surgical prep of animal, aseptic techniques, surgical approach, wound 
closure and suture removal plan. 
      
 
 10.6.b.  Location:  Where will surgeries be performed?  
      
 






Surgery                         
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Anesthesia                         
                         
                         
Post-op care                         
                         
                         
 
 10.6.d.  Anesthesia: Complete for each anesthetic drug used. 
Drug Dose Freq 
Route of 
Administration 
Isoflurane 4-5% 1ml/min Inhalation 
    
                        
 
10.6.e.  Anesthetic monitoring:  Check method(s) used for anesthetic 
monitoring. 
  Palpebral reflex   Toe pinch withdrawal 




Procedure last about 10 minutes, we will constant monitoring 
animals for 30 minutes after procedure started. 
 
10.6.f.  Paralytic agents:  Will paralytics be used?   
  Yes    If “yes” complete table below.   No  
Agent Dose Method of Monitoring 
                  
                  
                  
                  
 
 10.6.g.  Postoperative care:  Describe postoperative monitoring and care 
provided.  
First 
24 hours:       
 
Second 
24 hours:       
 
Thereafter:       
 
10.6.h.  Postoperative analgesia: Investigators should assume that procedures 
that cause pain in humans also cause pain in animals.  Please complete table 






bupivicaine/lidocaine mixture once At site of tail clip Locally 
    
    
 
10.7 Euthanasia:  What method or agent will be used to euthanize the animals?  
Include dosage and route of administration.  Also include a secondary method of 
euthanasia to ensure death.  Methods of euthanasia that are not considered 
“acceptable” by the latest version of the AVMA Panel on Euthanasia require 
scientific justification. 
Method: 
CO2 for retired breeders and incorrect genotyped weanlings. Decapitation 
for experimental mice and rats in order to collect brain samples for 
measurement of neuropeptides NPY and AGRP as well as their gene 




Drug:       
 
Route of 
administration:       
 
Secondary method:       
 
Who will perform 
euthanasia? Jun Zhou, Kathleen L McCutcheon 
 
Justification for use of “conditionally acceptable” methods of euthanasia: 
Animals will be euthanized at the end of the experiments by rapid decapitation. Due to 
the nature of the biochemical measurements to be performed, euthanasia of some 
animals must be carried out by decapitation without anesthesia. Stress and anesthesia 
interferes with the brain neuropeptides measurements of neuropeptides NPY and AGRP 
as well as their gene transcription.  Individuals who have had previous training and 





SECTION 11.  Procedure Checklist:  Check “Yes” or “No” to each of the following 
questions. The information you provide in this section is very important in highlighting 
specific points of your study that are important considerations for the IACUC in their 
review process.  
 
11.1.    Restraint:  Will animals be restrained?  (Restraint refers to immobilization or 
other restrictions to normal movement beyond momentary holding for injections, 
etc.) 
  YES      NO 
 
If “yes” how? 
Body fat will be measured by NMR without anesthesia 
For tail tip collection for genotyping, the mouse is restrained briefly and 
2-3 mm of the distal tip of the tail is rapidly excised with a sterile scalpel 
blade or sharp scissors 
 
How long? Less than 1 minute 
 
Describe monitoring during restraint 
period. Respiratory rate 
 
Who is responsible? Jun Zhou, Kathleen McCutcheon 
 
11.2. Animal Transport:  Will it be necessary to take live animals outside of 
Comparative Biology?  If animals are removed from Comparative Biology they 
cannot return. 
   
 YES    NO 




Justification:       
 
List rooms where animals will be 
taken:       
 
How long will they be kept in laboratory? Animals cannot be held outside of 
Comparative     
Biology for greater than 12 hours without IACUC 
approval.       
List procedures performed on 
animals:       
 
 
11.3. Food and water restriction:  Will food and/or water be withheld? (Please refer 
to the IACUC Policy Statement on food and water restriction posted on PINE 
under IACUC) 
 
 YES      NO 
 
If “yes” for how 
long? 
Overnight – up to 12 hours 
 
11.4. Blood collection:  Will blood be collected?* 
 
 YES      NO 
 
If “yes”:   
How often? Once , at the end of experiment after decapitation  
What is the maximum number of collections on a given 
animal?   1 
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What is the maximum volume per collection? All  
What collection technique will be used? Truck blood 
Who will perform collection? 




* Guidelines for blood collection.  The single blood collection limit is 10% of the 
animal’s estimated blood volume (6ml/100g bw), which for a mouse is 60 µl/10g 
of body weight and for a rat is 600 µl/100g of body weight.   The repeat blood-
sampling limit is the volume equal to 1.5% of the animal’s body weight per 2 
weeks.  Collections exceeding these limits require scientific justification. 
 
11.5. Animal Breeding:  Will breeding of animals be part of this protocol? 
 




What breeding scheme (pairs, trios, harem) will be 
used? Pair, trio and harem 
Who will be responsible for breeding 
animals?  Jun Zhou and  Kathleen L McCutcheon 
 
Who will be responsible for maintaining records and reporting use of animals 
generated 
in breeding colony to Comparative Biology 
office? 
Kathleen L McCutcheon and Jun 
Zhou 
 
What will the disposition of excess offspring or animals of incorrect genotype? 
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Culled – CO2 if necessary. Excess mice will be used to determine dosage for 
experiments      
 
 
11.6. Genotyping:  Will collection of tail tips or other tissue be required for 
genotyping? 
 
 YES      NO 
 
If “yes” describe technique and what anesthetics/analgesics will be used. 
Mice will be restrained briefly and 2-3 mm of the distal tip of the tail is rapidly excised 
with a sterile scalpel blade or sharp scissors. Before the mouse is returned to the cage, 
the end of tail is touched to a silver nitrate cauterizing stick to minimize bleeding and 
dipped in bupivicaine/lidocaine mixture as a local anesthetic.      
 
11.7. Identification:  Will individual animals be identified?  
 
 YES      NO 
 
If “yes” how? (e.g. ear punch, ear tag, tattoos) 
Breeder mice will be ear punched for identification. Weanlings will be ear punched at 
weaning before genotyping 
 
 
11.8. Adverse effects:  Do you anticipate any adverse effects of the experimental 
procedures on the animals? 
 
 YES      NO 
 
If “yes”, list the possible effects (e.g., pain, discomfort, % weight loss, maximum 
tumor size, fever, minimum packed cell volume, etc) and how they will be 




• Minimum weight loss due to overnight fasting. 
• Prolonged housing in stainless steel cage, a PVC tube will be provided for resting 
surface and animals will be monitored when they are weighted. 
• Transit pain due to tail tips and intraperitoneal injection 
• Temporary respiratory arrest due to capsaicin injection. The breathing will 
restart spontaneously or with the help of gentle chest massage. The entire 
procedure is carried out under deep Isoflurane anesthesia. Ten minutes after 
resumption of spontaneous breathing, anesthesia is discontinued and animals 
are allowed to recover. 
   
11.9. Death as an endpoint:  Is death an endpoint in your experimental procedure?  
Note: Death as an endpoint refers to experiments in which animals die as a direct 
result of the experimental manipulation, not due to euthanasia at the end of a 
study, e.g. acute toxicity testing, assessment of virulence of pathogens, 
neutralization tests for toxins. 
 YES      NO 
 
If “yes” provide scientific justification. 
      
 
11.10. Emergency treatments:  Are there emergency treatments by the Comparative 
Biology veterinary staff that would not be allowed? 
 
 YES      NO 
 
If “yes”, list treatments not allowed.  
Contact investigators. Antibiotics, stress, and some medications will interfere with 
experiments 
 
11.11. Antibody production:  Will animals be used for antibody production? 
 




If “yes”, list adjuvants to be used.   
      
 
For use of Complete Freund’s Adjuvant provide scientific justification.   
      
 
11.12. Exotic species:  Are you using wild or exotic species for which permits are 
necessary? 
 
          YES      NO 
  
ATTACH COPY of permits.  (Permits are required for protocol approval.) 
 
SECTION 12. Animal Management: 
 
Check all applicable below: 
CARE OF SICK ANIMALS DISPOSAL OF DEAD ANIMALS 
 Call Investigator 
 Clinician to Treat 
 Euthanasia 
 Call Investigator 
 Necropsy 
 Disposal 
List any special requirements for disposal?        
 
SECTION 13.  Disposition of Animals:  (What will be done with animals at the 
conclusion of the project? Check appropriate boxes.) 
 
 Animals will be euthanized. 
 Animals may or will be TRANSFERRED to another IACUC-approved protocol(s).   
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Protocol Number:       
 Appropriate transfer forms must be completed and submitted to the Comparative Biology Office 
when animals are transferred.   
  
SECTION 14.  Narrative Statements:  Federal regulations mandate that you provide a 
written narrative statement regarding whether the experiments described are 
unnecessarily duplicative, and whether you have considered alternatives for those 
procedures causing pain and distress.   
 
14.1. Provide a narrative statement in the box below indicating that the proposed 
experiments do not unnecessarily duplicate previous experiments.  In this 
statement, include sources used to make such a determination (e.g., Databases, 
workshops, expertise in the field, etc). 
After search electronic database, we confirm that te proposed studies are novel and will 
not unnecessarily duplicate previous experiments. 
 
If your source is an electronic database(s), complete the following boxes. 
Date Search Completed:  04-01-2006 
Database(s) Searched:  Medline 
Keywords:  Resistant starch, PYY, GLP-1, knock out, receptor  
Years covered in search:  1966-present 
 
For Type B or C protocols answer 14.2 and 14.3 if you indicated Type B or C in Section 
8. 
 
14.2. Provide a narrative statement, in the box below, indicating whether or not you 
have considered alternatives to procedures producing more than momentary or 
slight pain or distress.  Indicate what those alternatives were and why they are 
not appropriate. 
We have considered alternative procedures, but nonethat are appropriate for test our 
hypothesis. 
 
14.3 List the sources used to make the determination in 14.2.  If your source is an 
electronic database complete the boxes below. 
 




Date Search Completed:  04-01-2006 
Database(s) Searched:  Medline 
Keywords:  Resistant starch, PYY, GLP-1, knock out, receptor 
Years covered in 
search:  1966-present 
 
SECTION 15.  Investigator Training: In accordance with IACUC policy, all personnel 
conducting animal-based research must attend a Comparative Biology/IACUC Orientation 
Course.  The principle investigator is responsible for training for skills specific to their research 
project.  Indicate individual responsible for this training below. 





If no, who will do 
training? 
Jun Zhou  Y  N       
Kathleen L McCutcheon 
 Y  N       
Anne Raggio  Y  N       
 
NOTE:  All personnel must complete Comparative Biology’s training course in order to 










AIN-93G  American Institute of Nutrition- 93 Growing diet 
BMI   Body mass index 
CVD   Cardiovascular disease 
EC   Energy control 
GIP   Gastric inhibitory peptide 
GLP-1   Glucagon-like peptide-1 
HDL   High-density lipoprotein 
HF   High fat 
HRT   Hormone replacement therapy 
IOM   Institute of Medicine 
LDL   Low-density lipoprotein 
LF   Low fat 
NF- κB  Nuclear factor-kappa B 
NMR   Nuclear magnetic resonance  
NPY   Neuropeptide Y 
OVX (OV)  Ovariectomized 
PYY   Peptide YY 
RER   Respiratory exchange ratio 
RS   Resistant starch 
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RQ   Respiratory quotient 
SCFA   Short-chain fatty acid 
SH   Sham operation 






















Body Mass Index (BMI)  mass (kg)/height2 (m2) 
Cecum the beginning part of the large intestine that receives waste 
material from the small intestine 
Glucagon-like Peptide-1 (GLP-1) gastrointestinal peptide and hormone that acts in inhibiting 
food intake 
Obesity     having a BMI of ≥30 
Overweight    having a BMI of 25-29.9 
Peptide YY (PYY) gastrointestinal peptide and hormone known for its 
anorectic properties 
Respiratory Exchange Ratio (RER) ratio between CO2/%O2 used to indicate which fuel is 
being oxidized for energy production in the body 
Resistant starch (RS) a type of starch that is resistant to the effects of digestive 
enzymes and is not digested in the small intestine, but 
fermented by microflora in the large intestine 
Respiratory Quotient (RQ) an indicator of which fuel (carbohydrate or fat) is being 
metabolized to supply the body with energy at the cellular 
level 
Short-Chain Fatty Acids (SCFA) end-product produced by fermentation of resistant starch in the 
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